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The endocannabinoid system has been historically targeted for medicinal 
purposes through the use of cannabis. Two cannabinoid receptors, CB1 and CB2, have 
been identified as the mediators of the biological effects of the main psychoactive 
component in Cannabis sativa; delta-9-tetrahydrocannabinol. The CB1 receptor is a class 
A G-protein coupled receptor (GPCR), and is the most abundant neuro-modulatory 
receptor in the CNS. With its location at presynaptic termini, it regulates the function of 
other receptors, including the dopamine, serotonin, GABA, opioid and glutamate 
receptors. 
Many potential therapeutic applications targeting the CB1 receptor are under 
investigation. However, the unformed knowledge in drug-receptor interactions at the 
molecular level, and in the CB1 receptor signaling properties, has hampered the transition 
of many synthesized CB1 receptor agonists and antagonists to clinical use. In the studies 
to be presented, computational and mutational methods are employed to improve our 
understanding of the CB1 receptor structure, its conformational changes during 
activation, and the dynamics of drug-receptor interaction. 
In the first chapter, background information on the CB1 receptor is provided; 
including its structure, drugs that act at the CB1 receptor, G-protein and β-arrestin 
mediated signaling pathways, as well as, CB1 receptor regulation by other proteins.  
The second chapter includes a discussion of the biased signaling through class A 
GPCRs in general and through the CB1 receptor specifically. A set of hypothesis-driven 
mutations on the CB1 receptor yielded a CB1 receptor that exhibits biased signaling 
through the β-arrestin pathway. Results from this study provide better understanding of 
the molecular mechanisms of biased signaling at the CB1 receptor specifically, and in 
Class A GPCRs in general. In addition, biased mutants developed here should assist 
structure-based drug design of CB1 receptor ligands with β-arrestin functional selectivity. 
In the third chapter, molecular dynamics simulations are presented that were used 
to investigate the docking of 5-(4-chlorophenyl)-N-[(1R,2R)-2-hydroxycyclohexyl]-6-(2- 
methoxyethoxy)-3-pyridinecarboxamide (14h) inside the CB1 receptor. 14h has been 
described previously as a peripherally selective, high affinity CB1 receptor antagonist. 
However, the compound exhibits higher affinity for the human CB1 receptor compared to 
rodent CB1. Recent inactive state crystal structures (PDB ID: 5TGZ, 5U09) of the CB1 
receptor have been published showing the membrane proximal region of the N-terminus 
invading the receptor binding pocket, steering an important interaction site (K3.28) away 
from binding pocket. Thus, results from the docking study will help in the remodeling of 
the CB1 receptor’s N-terminus based on a mutational study that identified an N-terminal 
residue (M106 in rodent CB1 compared to I105 in human CB1) as the determinant of the 
species differential affinity of 14h at the CB1 receptor. 
The fourth chapter is focused on the biarylpyrazole derivative; 5-(4-
Chlorophenyl)-1-(2,4-dichloro-phenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-
carboxamide (SR-141716A (SR)). SR is a potent and a selective CB1 receptor antagonist 
and inverse agonist. The lack of force field parameters for SR has hampered the study of 
its interaction dynamics with the receptor in a lipid bilayer. This work describes the 
development of missing CHARMM force field parameters for SR based on a previously 
published parameterization method for drug-like molecules, as well as an all atom MD 
simulation study of SR in a fully hydrated bilayer. Generated parameters were successful 
in reproducing target data from SR crystal structures equilibrated at the MP2/6-31G* 
level of theory. MD simulations show that SR can adopt multiple orientations in the lipid 
bilayer, it can rotate in all directions and move freely between leaflets.  
Advances in crystallization and expression techniques made the crystallization of 
the CB1 receptor possible. However, those techniques, as well as, the static nature of the 
crystal structures, compromise the structural information for the receptor and undermine 
the dynamics of drug-receptor interactions. Computational, as well as, mutational studies 
would provide ancillary information that enhance our understanding of the CB1 receptor. 
Current studies increase our molecular level understanding of the conformational changes 
that accompany CB1 receptor activation. They also highlight the dynamics of drug-
receptor interactions in a bilayer. Results from these studies will aid the development of 
new ligands that target the CB1 receptor. 
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CHAPTER I 
 
INTRODUCTION 
 
 
Overview 
The CB1 receptor is a class A (Rhodopsin-like) GPCR that was first determined 
and characterized as the receptor protein for Δ9-THC -the major psychoactive constituent 
in Cannabis Sativa (Marijuana)- from rat brain preparations in 1988.[2] Cloning of the 
CB1 receptor from rat cerebral cortex[3] followed by cloning of human CB1 receptor 
from brain stem[4] prompted an ongoing research in the cannabinoid field. Another 
cannabinoid receptor subtype (CB2) was identified in 1993 that shows 44% overall 
identity to human CB1 receptor and 68% identity in the transmembrane region.[5] The 
CB1 receptor is highly expressed in the central and the peripheral nervous system, with 
high concentrations in the basal ganglia, cerebellum, cerebral cortex, hippocampus, and 
the emetic centers in the brain stem. An expression pattern that correlates with the 
analgesic, cognitive, psychomotor, and anti-emetic effects of cannabinoids. In addition. It 
is also expressed in the nucleus accumbens and ventral tegmental areas which are 
involved in reward, and food intake. On the other hand, the CB2 receptor is located 
primarily throughout the immune system.[6-9] 
Many potential therapeutic applications for CB1 agonists are under investigation 
including anti-emesis and appetite stimulation for AIDs patients, symptomatic relief of 
neuropathic pain in patients with multiple sclerosis and spinal cord injury, and, inhibition 
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of angiogenesis and growth of malignant tumors. However, psychoactive side effects 
limit the use of these agonists. 
CB1 receptor ligands have been shown to induce a complex pattern of 
intracellular effects that are ligand as well as cell-specific. Binding of a ligand induces 
distinct conformational changes in the receptor that will eventually translate into distinct 
intracellular signaling pathways through coupling to different intracellular effector 
proteins that can mediate receptor desensitization, trafficking, and signaling. The 
complex cellular components as well as concomitant expression of other proteins that 
either regulate the CB1 receptor or are regulated by the CB1 receptor will affect 
therapeutic outcome of targeting the CB1 receptor.   
This chapter will be focused on CB1 receptor structure, ligands, signaling, and 
regulation by other intracellular proteins to provide the basis for the three subsequent 
chapters in this dissertation. 
 
Cannabinoid Receptors Phylogeny and Structure 
Cannabinoid receptors share the general class A GPCRs’ topology that includes an 
extracellular N terminus, seven transmembrane helices (TMHs) joined by extracellular 
(EC) and intracellular (IC) loops of varied lengths, and an intracellular C terminus that 
begins with short alpha helical segment (Helix 8) oriented parallel to the cell membrane. 
The binding site for the endogenous ligand is generally formed by the EC core within the 
TMH bundle, and may extend to EC loops, referred to as the orthosteric binding site. 
Ligands may also bind to distinct (allosteric) binding sites in the receptor. 
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Figure 1. Helix Net Representation for the hCB1 Receptor. Disulfide bonds within the 
second extracellular loop and the N-terminus are yellow labeled. 
 
 
Different phylogenetic studies and multidimensional scaling analysis of Class A 
GPCRs classify cannabinoid receptors (CB1/CB2) into one cluster of class A GPCRs 
along with the endothelial differentiation G-protein coupled receptors (EDGRs) 
(including Sphingosine 1-phosphate receptor (S1P) and Lysophosphatidic acid 
receptor(LPA)).[10-13] Receptors from those families recognize lipid-derived ligands and 
share common sequence divergence from other Class A GPCRs. Specifically, the absence 
of helix kinking proline residues in TMH2 and TMH5, and the absence of disulfide 
bridge between EC-2 loop and C3.25 at the EC end of TMH3. Instead, they share an 
internal disulfide bridge in the EC-2 loop, a conserved PxxGWN motif at the EC end of 
TMH4 in addition to a Y5.39 that pi-pi stack with W4.64 in that motif resulting in a 
similar conformation of the EC2 loop in those receptors as can be seen in their crystal 
structures.[14-17] At the binding site, they share a common basic residue (K/R 3.28) on 
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TMH3 and an aromatic residue (F/Y 2.57) on TMH2. In addition, the S1P1 receptor is 
like CB1/CB2 in the presence of E1.49 at TMH1. E1.49 has been reported as the site of 
interaction of pregnenolone (an endogenous negative allosteric modulator that protects 
the brain from cannabis intoxication) with CB1,[18] while the LPA1 receptor shares a 
W5.43 that has been shown to affect antagonist binding to the cannabinoid receptors.[19] 
 
Endocannabinoids 
The CB1 receptor is located primarily on presynaptic termini, it acts in response 
to endogenous arachidonic acid derivatives (endocannabinoids) synthesized on demand 
following postsynaptic depolarization, these are N-arachidonoylethanolamine 
(Anandamide, AEA) and sn-2-arachidonoylglycerol (2-AG), (see Fig. 2).[20-22] 
Activation of CB1 receptor by 2-AG modulates two short-term forms of synaptic 
plasticity; depolarization induced suppression of inhibition (DSI) and depolarization 
induced suppression of excitation (DSE). Thus, 2-AG acts as retrograde messenger that 
inhibits the ongoing release of GABA and Glutamate from presynaptic neurons.[23] 2-
AG and AEA are rapidly degraded enzymatically by monoacylglycerol lipase (MAGL) 
and the fatty acid amide hydrolase (FAAH).[24] 
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Figure 2. Endogenous CB1 Receptor Ligands. 
 
 
CB1 Receptor Ligands 
Non-endogenous CB1 receptor agonists that target the orthosteric binding site of 
the receptor are grouped into the classical cannabinoids (e.g., Δ9-THC and (-)-11-
hydroxy-Δ8-THC-dimethylheptyl (HU210)), non-classical cannabinoids (e.g., ([2-
[(1R,2R,5R)-5-hydroxy-2-(3-hydroxy propyl)cyclohexyl]-5-(2-methyloctan-2-yl)phenol] 
(CP-55940)), and the aminoalkylindoles (e.g., ((R)-(1)-[2,3-dihydro-5-methyl-3-(4-
morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-napthalenylmethanone 
(WIN55212-2)). The first CB1 antagonist ([5-(4-chlorophenyl)-1-(2,4-dichloro-phenyl)-
4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide] (SR141716A)), was described 
by Sanofi Recherche in 1994, it displays nano-molar CB1 affinity and acts as a selective 
CB1 inverse agonist (see Fig. 3).[25, 26]  
 
 
 
6 
 
Figure 3. Non-Endogenous Ligands for the CB1 Receptor. Agonists (CP-55941, 
HU210, ∆9-THC, WIN-55212) and the antagonist/inverse agonist SR-141716A. 
 
 
Signaling via the CB1 Receptor 
Activation of the CB1 receptor inhibits forskolin-stimulated adenylyl cyclase via 
coupling to PTX-sensitive G-protein (Gαi/o), and increases phosphorylation of 
extracellular signal-regulated kinase 1/2 (pERK1/2) via G-protein dependent and β-
arrestin-1 dependent pathways.[27] Gαi/o mediated decrease in cAMP upon CB1 
activation activates G-protein-coupled inwardly rectifying potassium channels (GIRKs) 
and inhibits N-type and P/Q type voltage-gated calcium channels, inhibiting presynaptic 
neurotransmitter release.  Stimulation of CB1 also leads to phosphorylation and 
activation of mitogen-activated protein kinases (MAPK), such as p38 MAPK and c-Jun 
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N-terminal kinase, which can regulate nuclear transcription factors.[28-30] While CB1 
couples mainly through Gαi/o type G-protein, coupling to other G-protein types under 
special circumstances has been also reported. As an example; coupling to Gαs has been 
suggested in striatal neurons and in transfected CHO cells treated with PTX as well as 
in L341A/A342L mutant CB1 receptor accounting for the increase in intracellular cAMP 
upon treatment with CB1 agonist.[31, 32] The increase in cAMP has been attributed in a 
later study at Howlett’s Lab to reduced Gi/o function.[33] In addition, WIN55212-2 has 
been shown to increase intracellular calcium in transfected HEK293 cells and in cultured 
hippocampal neurons via coupling to Gαq/11.[34] 
 
Phosphorylation and Subsequent β-Arrestin Recruitment 
Mammalian cells express seven isoforms of G protein-coupled receptor kinases 
(GRKs), those are GRK1-7. While GRK1/7 are primarily found in the retina and regulate 
opsins, other GRKs (GRK2,3,5,6) are widely expressed in the body and in neuronal cells, 
with limited expression of GRK4 to the cerebellum, testis and kidneys.[35, 36] GRK2 
and GRK3 have a pleckstrin homology domain that allows their translocation to the 
plasma membrane by binding to phosphatidylinositol lipids such as phosphatidylinositol 
(4,5)-bisphosphate (PIP2) or to the βγ-subunits of activated G-proteins. GRKs 4, 5, and 6 
lack the pleckstrin homology domain but are primarily attached via a lipidation to the 
plasma membrane. In canonical GPCRs signaling pathway, GRKs phosphorylate serine 
and/or threonine residues at the IC domain of agonist-activated receptors, specifically at 
the C-terminus and/or the third IC loop.[36] Different GRKs have been reported to result 
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in distinct phosphorylation patterns at the IC domain of GPCRs that were correlated with 
the functional selectivity of the activated receptor upon agonist binding.[37] 
β-arrestin recruitment to phosphorylated receptor redirects the G-protein 
dependent signaling state of the receptor to other possible states depending on the 
receptor itself, the phosphorylation pattern which determines the type of the β-arrestin 
being recruited to the receptor, the agonist specificity, as well as intracellular 
components. The two non-visual arrestins; β-arrestin-1 and β-arrestin-2, are expressed 
ubiquitously in mammalian tissues and mediate GPCRs desensitization, endocytosis, 
ubiquitination, or the G-protein independent signaling.[38, 39] β-arrestin recruitment to 
phosphorylated receptor may sterically inhibit G-protein coupling to the activated 
receptor, thus quenching G-protein signal and reducing receptor’s response to repeated 
stimulation, known as receptor desensitization. On the other hand, β-arrestins may act as 
scaffolding proteins in which they can mediate clathrin-mediated receptor endocytosis by 
binding to β(2)-adaptin and clathrin, or they can mediate G-protein independent 
intracellular signaling pathways by scaffolding the different mitogen-activated-protein-
kinase (MAPK) signaling modules, including the ERK1/2, p38MAPK, and c-Jun N-
terminal kinases, as well as scaffolding the Src family tyrosine kinases and protein 
phosphatases.[35, 36, 39, 40] 
In addition, the non-canonical, G-protein independent β-arrestin recruitment to 
GPCRs has been also reported. The reported ability of GRK5 and GRK6 to 
phosphorylate inactive receptors may explain the ability of β-arrestins to recruit to 
GPCRs in a G-protein independent way.[41]  
9 
Recent studies on the β2AR and the vasopressin receptor using mutational and 
electron microscopic techniques, reported two possible interaction scenarios of the 
arrestins with the IC domain of the receptors; the tail-conformation where the arrestin is 
bound to the C-terminus of the receptor only, and the core-conformation where the 
arrestin is bound to both the C-terminus and the cytoplasmic core of the receptor. 
Interacting in the tail conformation, arrestins preserve their ability to mediate G-protein 
independent signaling, receptor internalization, but not desensitization.[42] Interestingly, 
GPCR-G-protein-β-arrestin megaplexes have been reported, in which the arrestin is 
engaged to the GPCR in the tail conformation allowing a concomitant binding of the G-
protein with the receptor, these megaplexes explain the ability of some GPCRs to activate 
G-proteins from internalized compartments.[43] In addition to GRKs, second messenger-
dependent protein kinases (PKA, and PKC) have been reported to phosphorylate GPCRs 
at the IC domain, attenuating G-protein dependent signaling through GPCRs.[44-47]  
In the recently published crystal structure of Rhodopsin in complex with the 
visual arrestin, authors identified a phosphorylation pattern in the C-terminus that is 
required for effective recruitment of arrestins to the receptor. A short code (PxPxxP/E/D), 
or a long code (PxxPxxP/E/D) were identified in which the P represents phosphorylated 
serine or threonine residues, while the x is any amino acid residue. Identified pattern of 
negatively charged amino acid residues ensures high affinity interaction with the three 
positive pockets at the N-temrinal domain of activated arrestin.[48] The crystal structure 
of β-arrestin-1 bound to phosphorylated peptide segment of the vasopressin receptor’s C-
terminus was also in agreement with proposed motif.[49] 
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The C-terminus in the CB1 receptor contains multiple serine, threonine, aspartate 
and glutamate residues. According to the previously proposed phosphorylation code, the 
membrane proximal segment of the C-terminus which contains D423-NSMGDS-D430 
(hCB1 numbering) and the membrane distal segment which contains T460-
MSVSTDTSA-E470 are two possible interaction sites at the C-terminus of the CB1 
receptor with the β-arrestins. The central segment, on the other hand, contains A439-A-
S441 in human / T440-A-S442 in rodents, which implies low if no interaction of the 
arrestins with the CB1 receptor at this region. 
Different studies that investigate the role of GRKs and β-arrestin-1/2 in the 
desensitization, internalization, or signaling via the CB1 receptor have been reported. 
Mackies lab demonstrated the role of GRK3 and β-arrestin-2 in CB1 receptor 
desensitization using Xenopus oocytes transfected with rat CB1. Attenuation of G-protein 
dependent Kir current during an 8 minutes exposure to WIN-55212 required co-
expression of both GRK3 and β-arrestin-2. In the same study, truncation mutants of the 
whole C-terminus (∆418), or (∆418-439) did not desensitize while truncation at 439 and 
at 460 could still desensitize. In addition, S426A, or S430A mutations significantly 
attenuated desensitization, while they had no effect on the internalization of the receptor 
evaluated in AtT20 cells treated with WIN-55212.[50] Subsequent study in HEK293 cells 
shown that the S426A/S430A mutant recruits β-arrestin-2 in a similar extent to the WT 
receptor, suggesting that the β-arrestin-2 recruitment to the proximal C-terminus confers 
receptor desensitization, while it can still recruit to the distal region of the C-terminus in 
the absence of phosphorylation at S426/S430. Thus, β-arrestin-2 recruitment does not 
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guarantee CB1 receptor desensitization.[51] In a different study, treatment with WIN-
55212 resulted in desensitization of CB1 receptor lacking distal residues 419-460 
transfected into CB1 knockout autaptic hippocampal neurons, distal segment of the C-
terminus thus was directly attached to the transmembrane bundle.[52] It could be 
concluded from those studies, that the desensitization is linked to β-arrestins being 
recruited close to the CB1 receptor transmembrane domain, which may imply β-arrestin 
core conformation binding to the CB1 receptor at the proximal C-terminus that would 
sterically uncouple G-protein from the CB1.   
In further studies on the proximal C-terminus region of the CB1, a recent study 
using the S426A/S430A CB1 receptor mutant expressed in HEK293 cells, demonstrated 
an interesting shift in the functional selectivity of WIN-55212 from inducing biased G-
protein-dependent pERK1/2 signal at the WT receptor to inducing biased β-arrestin-1-
dependent pERK1/2 signal in the mutant receptor. On the other hand, 2-AG induced G-
protein dependent followed by β-arrestin-1 dependent pERK1/2 signal in the WT 
receptor, while its induced pERK1/2 signal was totally β-arrestin-1 dependent in the 
S426A/S430A CB1. The same study has also demonstrated significantly higher 
recruitment of β-arrestin-1 to the S426A/S430A CB1 compared to the WT receptor, and a 
weaker recruitment of β-arrestin-2 to the S426A/S430A CB1 compared to the WT 
receptor 5 minutes after treatment with WIN-55212.[53] However, an 
immunoprecipitation study from Howlett’s lab, demonstrated that only the proximal 
phosphorylated C-terminal peptide segment (T419-H436 phosphorylated at S426/S430) 
competed for the CB1 receptor association with β-arrestin-1, while both phosphorylated 
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proximal peptide segment and the distal peptide segment (V460-L473 phosphorylated at 
T468) competed for the association with β-arrestin-2, the study was done using cultured 
N18TG2 neuroblastoma cells.[54] Those results contradict with the ability of β-arrestin-1 
to recruit to the S426A/S430A CB1 receptor. However, the ability of β-arrestin-2 to bind 
both the proximal and the distal regions of the CB1 receptor’s C-terminus could still be 
valid. 
In vivo, S426A/S430A mutant mice were more sensitive to the anti-nociception 
and hypothermic effects induced by ∆9-THC and endocannabinoids, with delayed 
tolerance and increased ∆9-THC-dependence, while cultured autaptic hippocampal 
neurons from mutated mice showed enhanced WIN-55212-mediated DSE and reduced 
agonist-mediated desensitization of DSE.[55] 
Reported studies on the distal segment of the C-terminus evaluated its role in 
receptor internalization as well as desensitization. Mackeis’ lab used AtT20 cells stably 
transfected with truncated rat CB1 receptor mutants and demonstrated that receptors 
lacking the last 10 amino acid residues (V464Z) could internalize in a similar extent to 
the WT receptor following WIN-55212 treatment. However, receptor lacking the last 14 
amino acid residues (V460Z) did not internalize. Internalization in this study was 
determined using immunofluorescence confocal microscopy and was determined to be G-
protein independent since pretreatment of the cells with cholera toxin or PTX did not 
prevent internalization.[56] In a later study, the V640Z CB1 receptor did not internalize 
and failed to recruit β-arrestin-2 to the membrane in AtT20 cells treated with WIN-55212 
or CP-55940. However, V640Z CB1 receptor expressed in HEK293 cells internalized to 
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the same extent as the WT receptor and could recruit the β-arrestin-2 to the 
membrane.[57] From previous discussion, we could conclude that β-arrestin-2 could bind 
to both the proximal and the distal regions of the CB1 receptor’s C-terminus, truncation 
of distal C-terminus did not affect β-arrestin-2 recruitment in HEK293 cells, suggesting 
that it has been recruited to the proximal C-terminus. A possible explanation that β-
arrestin-2 could not recruit to the proximal C-terminus of V640Z receptors expressed in 
AtT20 cells could be the presence of other CB1 receptor coupling proteins that compete 
with the β-arrestins for the C-terminus, such as the CRIP1A and the SGIP1 proteins 
which are known to compete with the β-arrestins on binding to the CB1 receptor’s C-
terminus.[54, 58] Thus, the only available interaction site at the proximal C-terminus in 
V640Z receptors would be occupied by those proteins that are absent in HEK293 cells.  
To determine critical phosphorylation site residues required for internalization, 
different mutations were introduced to the distal C-terminus region (T460-
MSVSTDTSAEA-L473). T461A/S463A, S465A/T466A, and T468A/S469A double 
mutants showed similar extent of internalization and efficient β-arrestin-2 recruitment to 
the plasma membrane compared to the WT upon treatment with CP-55940. However, 
mutating four or all six putative phosphorylation sites (T461A-T466A and T461A-
S469A) significantly attenuated CP-55940 induced receptor internalization, and did not 
show translocation of β-arrestin-2 to the membrane.[57] Results described here are 
perplexing, since β-arrestin-2 could recruit to the V640Z mutant in HEK293 cells while it 
could not recruit to T461A-T466A and T461A-S469A mutants in the same cell line. On  
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the other hand, V640Z CB1 or T461A-S469A transfected into CB1 knock out autaptic 
hippocampal neurons did not desensitize following WIN-55212 or 2-AG treatment.[52] 
Finally, away from the C-terminus, the CB1 receptor’s IC3 loop has been reported 
to be phosphorylated at S317 by PKC in AtT20 cells transfected with rat CB1 receptor. 
Phosphorylation at S317 has been shown to attenuate CB1 mediated activation of Kir 
currents.[47] 
 
Reported GRKs that Phosphorylate the CB1 Receptor 
As discussed earlier, co-expression of GRK3 and β-arrestin-2 in oocytes have 
been reported to be essential for CB1 receptor desensitization of WT receptor but not 
receptors with truncations of the proximal C-terminus.[50] inhibition of GRK2 in 
N18TG2 cells reduced the internalization of CB1 receptor upon treatment with CP-
55940.[54] In another study, knocking down GRK3 or GRK2,3 in HEK293 cells 
expressing rat CB1 receptors significantly increased the pERK1/2 signal 15 minutes 
following WIN-55212 treatment, while they had no effect on the S426A/S430A mutant 
receptor. The same mutant induced significantly lower pERK1/2 signal following WIN-
55212 treatment in HEK293 cells with GRK4, GRK5, or GRK6 knock down. In the same 
study, WIN-55212 has been shown to induce G-protein dependent pERK1/2 signal in the 
WT receptor, and β-arrestin-1 dependent pERK1/2 signal in S426A/S430A mutant.[53] 
Results suggest that GRK3 phosphorylates the proximal phosphorylation sites in the CB1 
receptor C-terminus, specifically at S426 and S430. This phosphorylation results in 
desensitization of the receptor. Thus, knocking down of GRK3 would enhance G-protein 
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dependent pERK1/2 signal in WT receptor. On the other hand, β-arrestin-1 mediated 
signaling through the CB1 receptor has been reported to be from endocytic pits.[27] 
GRK4, GRK5, and GRK6 might be involved in the phosphorylation of the distal C-
terminus and could be necessary for receptor internalization into those endocytic pits, 
thus knocking down of those GRKs lowers the β-arrestin-1 mediated pERK1/2 signal in 
the S426A/S430A mutant.[53]  
 
Altering Cannabinoids Activities in β-Arrestin-1 and 
β-Arrestin-2 Knockout Mice 
 
In vivo studies evaluating the antinociceptive (tail flick assays) and temperature 
depressive effects of CB1 receptor agonists in β-arrestin-1 and β-arrestin-2 knockout 
mice, demonstrated that β-arrestins regulate cannabinoids sensitivity in agonist-selective 
manner, while they do not affect the density of CB1 receptors in brain membranes which 
was determined using radioligand binding assays.[59, 60] Deletion of β-arrestin-2 
increased ∆9-THC antinociceptive and temperature depressive efficacy, while it did not 
affect the efficacy of other ligands such as CP-55940, methanandamide, JWH-073 and O-
1812.[59] On the other hand deletion of β-arrestin-1 diminished the effects of CP-55940 
in both antinociception, and temperature-depression assays in mice, while it did not affect 
∆9-THC efficacy. Interestingly, CP-55940 produced greater stimulation of [35S]GTPγS 
binding to membranes from whole brain of β-arrestin1 knockout mice compared to the 
WT. this may indicate that the antinociceptive and the temperature depressive effects of 
CP-55940 are not G-protein dependent. In the same study, it has been demonstrated that  
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the tolerance development to chronic treatment with ∆9-THC or CP-55940 is not β-
arrestin-1 dependent.[60] 
 
Other Proteins Regulating the CB1 Receptor 
In addition to GRKs and β-arrestins, other intracellular proteins are known to 
regulate the CB1 receptor. The Src homology 3-domain growth factor receptor-bound 2-
like (endophilin) interacting protein 1 (SGIP1), is an 828 amino acid residues protein 
with N-terminal lipid-binding domain. SGIP1 has been shown to interact with the CB1 
receptor C-terminus. Association with the CB1 receptor was verified in-vivo using 
coimmunoprecipitation technique from rat brain homogenates, and in-vitro using BRET 
assay in HEK293 cells transfected with both the CB1 and SGIP1 protein, where similar 
extend of association has been observed in the presence or absence of CB1 receptor 
agonist. SGIP1 is expressed in different regions in the brain where it can overlap with the 
expression of the CB1 receptor. SGIP1 has been shown to inhibit clathrin-mediated 
endocytosis of the CB1 receptor. It has been also demonstrated that it enhances the CB1 
receptor association with β-arrestin-2 but not with b-arrestin-1, and it lowers WIN-55212 
induced PTX-sensitive ERK1/2 phosphorylation while not affecting CB1 receptor 
mediated Gαi/o/q activation.[58] In addition, it has been demonstrated to colocalize at 
presynaptic termini with the CB1 receptor in cultured cortical neurons, which may 
explain neuronal compartment-selective endocytosis in which rapid CB1 receptor 
internalization is observed in neuronal soma, while resistance to endocytosis is observed 
in presynaptic termini.[58, 61]  
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The cannabinoid receptor interacting protein 1a (CRIP1a) has been also 
demonstrated to interact with the C-terminus of the CB1 receptor. CRIP1a is a 164 amino 
acid residues protein with predicted palmitoylation site but not transmembrane domain, it 
has high expression in different brain regions including the cerebral cortex, cerebellum, 
hippocampus, hypothalamus, and caudate nucleus. In-vivo co-expression has been 
determined using coimmunoprecipitation technique from rat brain homogenates,[62] and 
colocalization with the CB1 receptor at presynaptic termini was also confirmed using 
immune-histochemical studies in transgenic mice cerebellum.[63] CRIP1a has been 
reported to attenuate agonist-induced CB1 receptor internalization,[63] and modulate 
CB1 mediated activation of G proteins in a subtype selective manner.[64] It has been also 
shown to compete with β-arrestins to the CB1 receptor C-terminus that could affect β-
arrestins mediated effects via the CB1 receptor.[54]
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CHAPTER II 
 
MUTATIONS AT THE INTRACELLULAR DOMAIN OF THE CB1 RECEPTOR 
BIAS ITS SIGNALING TOWARDS THE β-ARRESTIN PATHWAY 
 
Introduction 
Biased signaling through GPCRs has recently received a special attention in the 
field of drug research; this is due to the possibility of attaining different therapeutic 
effects and/or avoiding untoward effects while targeting the same receptor protein.[65] In 
GPCRs, biased signaling describes the ability of different ligands to stabilize distinct 
receptor states that vary the ability of the receptor to activate specific transducers, such as 
activation of different G-proteins and/or signaling through β-arrestins.  
Binding of an agonist to the receptor induces several conformational changes in 
the binding site which lead to distinct conformational changes in the IC domain of the 
receptor. These changes uncover the IC domains that are important for coupling to 
different IC effector proteins, thus determining the signaling pathway(s) of the receptor. 
Despite the tremendous variation in chemical structures of agonists that bind and 
activate class A GPCRs, those receptor proteins share common molecular activation 
mechanisms. A set of amino acid residues that are highly conserved at the majority of 
non-olfactory members (ligand-modulated receptors) of this class[66] are thought to act 
as molecular switches that dictate the conformational changes in the receptor upon ligand 
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binding and thus; dictating the functional selectivity and biased signaling of the receptor. 
Conserved amino acid residues include the following motifs; NxLV in TMH1, LAxAD in 
TMH2, D/ERY motif in TMH3, FxxCWxP in TMH6 and NSxxNPxxY motif in TMH7 
(see Fig. 4, and Table 1).  
Different mutations on class A GPCRs have been used to study multiple 
downstream signaling cascades from biased mutants. As mentioned in the first chapter, 
mutating two phosphorylation sites at the C terminus of the CB1 receptor (S426A, S430A 
in rat CB1) shifted WIN-55212-induced pERK signal via the CB1 receptor from being G-
protein biased to being β-arrestin-1 biased.[53] Mutations that included conserved amino 
acid residues were also employed; mutating the conserved DRY motif at the IC end of 
TMH3 into AAY biased the signaling of the CB1 receptor and the angiotensin-1A 
receptor towards the β-arrestin pathway[67, 68]. At the β-2-adrenergic receptor, a triple 
mutant that included two conserved tyrosine residues (T2.39F, Y3.51G, Y5.58A) 
exhibited β-arrestin biased signaling determined by measuring the pERK signal in 
HEK293 cells expressing WT or mutant receptor.[69] In addition, a recent mutational 
study on the δ-opioid receptor revealed interesting efficacy switching of Naltrindol from 
antagonist at the WT receptor into a potent β-arrestin biased agonist at D2.50A, N7.45A, 
and N7.49A mutants [70]. 
Other mutations that involve the conserved amino acid residues in class A GPCRs 
are abundant in the literature. However, their exact role in biased signaling is still not 
well understood because most of these mutations were evaluated for their canonical G-
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protein signaling efficacy only, while their efficacy in β-arrestin signaling is yet emerging 
in the literature. 
 In this study, three hypothesis-driven single point mutations on I2.43 and S7.57 
were proposed to elucidate the mechanism of biased signaling through the CB1 receptor. 
Those are I2.43A, I2.43T, and S7.57E. As being expected, mutants were successful in 
biasing the signaling of the CB1 receptor towards the β-arrestin signaling pathway. 
The elucidation of the specific conformational changes in the CB1 receptor that 
result in distinct subsets of downstream signaling pathways through G-protein or β-
arrestin, should increase our understanding of biased signaling in CB1 receptor in 
specific and in Class A GPCRs in general. In addition, the presence of biased CB1 
receptor mutants aids the search for potential therapeutic applications via the CB1 
receptor.  
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Figure 4. Location of Conserved Amino Acid Residues in Class A GPCRs. Residues 
displayed in green form an intact hydrophobic layer at the IC domain of the receptor in its 
inactive state. Residues that contribute to this hydrophobic layer are at locations 1.53, 
157, 2.43, 2.46, 3.43, 3.46, 6.37, 6.40, in addition to Y7.53
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Table 1. Conserved Residues and Motifs Presented in a Sample of Class A GPCRs.  
(* BW: Ballesteros–Weinstein residue numbering.[1]), Green highlight represents non-
polar amino acid residues, while yellow highlight represents polar amino acid residues. 
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Rho N F L T L L A V A D A E R Y W P Y F L I C W V P A A N P V I Y F R 
D3 N G L V V L A V A D S D R Y W P Y F I V C W L P N S N P V I Y F R 
D1 N T L V I L A V S D S D R Y W P Y F V C C W L P N S N P I I Y F R 
GPR119 N T L V T L A V A D S D R Y W P F F A L S W T P N S N P L I Y V R 
M2 N I L V L L A C A D S D R Y W P Y F I I T W A P N S N P A C Y F K 
LPAR1 N L L V M L A A A D S E R H W T Y F I I C W T P N S N P I I Y M S 
S1P1 N I F V I L A L S D S E R Y W L Y F I A C W A P N S N P I I Y M R 
CB1 N L L V I L A V A D S D R Y W L Y L I I C W G P N S N P I I Y L R 
CB2 N V A V I L A G A D S D R Y W L Y L L I C W F P N S N P V I Y I R 
Orx2 N V L V I L S L A D S D R W W P Y F A I C Y L P N S N P I I Y F R 
B2AR N V L V I L A C A D S D R Y W P Y F T L C W L P N S N P L I Y F R 
A2A N V L V V L A A A D S D R Y W P Y F A L C W L P N S N P F I Y F R 
B1AR N V L V I L A S A D S D R Y W P Y F T L C W L P N S N P I I Y F R 
MOR N F L V I L A L A D S D R Y W P Y F I V C W T P N S N P V L Y F K 
KOR N S L V I L A L A D S D R Y W P Y F V V C W T P N S N P I L Y F K 
23 
Methods 
Mutagenesis: The I2.43A, I2.43T, and S7.57E mutants of the GFP-tagged human 
CB1 (GFP-hCB1) in the vector pcDNA3 were constructed using the QuikChange site-
directed mutagenesis kit (Agilent, Wilmington, DE) as described by the manufacturer. 
DNA sequencing subsequently confirmed the presence of only the desired mutation. 
Cell culture and transfections: Human embryonic kidney (HEK293) cells 
(ATCC CRL-1573) were cultivated in growth medium consisting of Dulbecco’s 
Modified Eagle’s medium (DMEM) with 4.5 g/L glucose, L-glutamine and sodium 
pyruvate purchased from Corning (Corning, NY), and 10% fetal bovine serum (FBS) 
purchased from HyClone (Logan, UT). Cells were grown in 75cm2 flasks at 37°C and 5% 
CO2 until 80-90% confluent and then resuspended by incubation with 2ml of 1mM 
EDTA in phosphate-buffered saline (PBS). Growth medium was then added, and 
mechanical dissociation was performed. Cells were passaged weekly at a sub-cultivation 
ratio of 1:10. 
Stably transfected cell lines were obtained by transfecting HEK293 cells with 
wild-type or mutant GFP-hCB1 plasmids in a 24-well plate using Lipofectamine 2000, as 
described by the manufacturer (Invitrogen, Carlsbad, CA). Transfected cells were then 
resuspended and transferred to 100mm tissue culture dishes. On the next day cells were 
incubated in selection medium, containing growth medium and 800µg/ml G418 (Enzo 
Life Sciences, Farmingdale, NY). Cells were maintained in selection medium for 2 weeks 
before single colonies were selected for expansion. GFP-hCB1 expression was confirmed 
by analysis of GFP fluorescence. Briefly, cells were grown on glass coverslips and fixed 
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in 4% Paraformaldehyde for 20min at room temperature. Coverslips were mounted on 
microscope slides with Fluoromount-G mounting medium (Southern Biotech, 
Birmingham, AL) and imaged in an upright epi-fluorescence microscope (Nikon, Tokyo, 
Japan) at 20x magnification. 
In-cell western: Cells were grown to 90% confluence in 96-well plates and 
serum-starved with DMEM overnight before the assay. Pertussis toxin (Sigma, St. Louis, 
MO) 200 ng/ml treatment was administered overnight in DMEM while cells were serum-
starved. Cells were then incubated with room temperature HBSS (Corning) for 20min 
before treatment with CB1 agonist 2-arachidonoylglycerol (2-AG) obtained from NIDA 
Drug Supply in 0.1% dimethyl sulfoxide (Sigma) in DMEM. Cells were then fixed with 
4% Paraformaldehyde for 15min on ice and 45min at room temperature, permeabilized 
with 100% methanol at -20°C for 20min and incubated with LI-COR blocking buffer (LI-
COR; Lincoln, NE) for one hour and 30min with gentle shaking. Primary antibodies 
rabbit monoclonal anti-phospho-ERK1/2 (1:100; Cell Signaling Technology, Danvers, 
MA) and mouse monoclonal anti-GFP tag clone GF28R (1:500; ThermoFisher) were 
applied overnight in a cold room, and then secondary antibodies goat anti-rabbit IgG 
800CW (1:500; LI-COR) and goat anti-mouse IgG 680RD (1:500; LI-COR) were applied 
for 1h at room temperature. The plate was dried and then scanned using a LI-COR 
Odyssey IR Imager set at 169 µM resolution, 3.4 focus offset, and 6 to 7 intensities. Data 
were analyzed using Excel (Microsoft Corp., Redmond, WA) and Prism 4.0 (GraphPad 
Software, San Diego, CA) software. pERK signal normalized to the CB1 receptor 
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expression (GFP signal) at each time point and calculated as fold change with respect to 
the pERK normalized signal from vehicle treated WT expressing cells. 
 
Results 
Different reports have shown that the CB1 receptor activates the extracellular 
signal-regulated kinases (ERK1/2) via both G-protein and β-arrestin dependent pathways. 
[27, 53, 71-74] Treatment of the CB1 receptor by the endogenous ligand, 2-AG, resulted 
in an early PTX-sensitive phosphorylated ERK1/2 (pERK1/2) signal, followed by PTX-
insensitive pERK1/2 signal that was diminished using small interfering RNA vector 
against β-arrestin-1.[27, 53, 72, 73] 
In the current study, the three mutants were stably transfected into HEK293 cells 
and expression was evaluated by immunofluorescence technique, (see Fig. 5). CB1 
receptor endogenous ligand, 2-AG, has been used to evaluate the signaling paradigm of 
mutant CB1 receptors due to its ability to activate both signaling pathways. In-cell 
western immunolabelling of the pERK was used to measure 2-AG-induced pERK signal 
in HEK293 cells stably transfected with GFP-tagged WT and mutant CB1 receptors, with 
and without pretreatment with PTX, and at different time points. GFP protein was 
immunolabelled and its signal was used to normalize the pERK signal for the CB1 
receptor expression. At the WT receptor, treatment with 2-AG resulted in pERK signal 
that peaks at 15 minutes. Pre-treatment with PTX abolishes the 5 minutes pERK signal 
while significantly reduces the 10, and 15 minutes signal (see Fig. 6,7,8). In agreement 
with previous reports, results from the WT indicate that the 2-AG activates the G-protein 
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signaling pathway through the CB1 receptor resulting in an early (5 minutes) pERK 
signal that peaks at 10 minutes, subsequent phosphorylation of the CB1 receptor by 
GRKs calls for the β-arrestins and induces β-arrestin dependent pERK signal detected at 
10 minutes and extends beyond 30 minutes, while peaking at 15 minutes.[27, 53]  
At the molecular level, it could be inferred that the binding of 2-AG to the WT 
receptor induces a sequence of conformational changes in which the receptor adopts the 
canonical G-protein-coupling active state conformation in which the ionic lock is broken 
between TMH6 and TMH3, followed by β-arrestin-coupling active state conformation in 
which the ionic lock reforms while the IC end of TMH7 hinges out allowing interaction 
with the β-arrestin (see Discussion). Such conformational changes are protein-ligand 
dependent and are not affected by the pretreatment with PTX. Thus, the β-arrestin 
dependent pERK signal commences later than the G-protein dependent pERK signal at 
the WT type receptor treated with 2-AG.  
I2.43A and I2.43T mutants exhibit β-arrestin biased signaling paradigm: In 
class A GPCRs, the amino acid residue at 2.43 is a highly conserved amino acid residue 
that is part of the hydrophobic layer at the IC domain of the receptor, and being packed 
against Y7.53 in the receptor’s inactive state. The I2.43A and I2.43T mutations were 
expected to bias the signaling of the CB1 receptor towards the β-arrestin pathway. This is 
because those mutations would disturb the hydrophobic layer in the TMH1/2/7 region, 
and would enhance the trans rotameric state of Y7.53 by either reducing the steric clash 
at that region (I2.43A mutant), or via forming H-bond interaction with Y7.53 (I2.43T 
mutant) (see Discussion).  
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Dose response curves at the WT and I2.43A and I2.43T mutant receptors were 
determined 15 minutes after treatment with 2-AG. Emax for the mutants were 
comparable to the WT receptor, this is due to the normalization to the CB1 receptor 
expression. However, pEC50 value from the I2.43T mutant receptor has shown 
statistically significant difference from the WT receptor, with pEC50 values for the WT 
and the I2.43T mutant receptors being 4.73 ± 0.09 and 5.16 ± 0.06 respectively. The 
pERK signal for the I2.43A and I2.43T mutants pretreated with PTX was not statistically 
significant from the mutant receptors without PTX treatment at all time points, 
suggesting that both mutants signal through β-arrestin only.  
 
 
 
Figure 5. Stable Expression of WT and Mutant CB1 Receptors in HEK293 Cells. 
Cells non-transfected, or stably transfected with WT and mutant GFP-tagged hCB1 
receptor. Cells were imaged under epi-flourescence microscope. 
 
 
For the I2.43T mutant, it can be noticed that unlike the WT receptor, the β-arrestin 
dependent pERK signal through this mutant is detected at 5 minutes, this indicates that 
the receptor adopts the β-arrestin-coupling active state conformation directly after 2-AG 
binding. However, 5 minutes pERK signal from the I2.43A mutant was not statistically 
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different form the 0-time point, and the mutant results in a statistically significant 10 
minutes signal when compared to the WT receptor for cells pretreated with PTX.  
 
 
Figure 6. I2.43T Mutant Exhibits β-Arrestin Biased Signaling Paradigm. A) dose 
response curves 15minutes following treatment by 2-AG for the WT and I2.43T mutant 
CB1 receptor with pEC50 values of 4.73 ± 0.15 and 5.16 ± 0.09 respectively (pEC50 
values determined by non-linear regression using least squares fitting analysis, n=3). B) 
HEK293 cells expressing GFP-hCB1 treated with 7µM 2-AG. Statistical significance of 
the differences was assessed using two-way analysis of variance and test., */#, p _ 0.03; 
**/##, p _ 0.002; ***/###, p _ 0.0002. C) In-cell western blots for HEK293 cells stably 
transfected with GFP-tagged WT and I2.43T mutant CB1 receptor before and after 
treatment with 2-AG. D) In-cell western blots for HEK293 cells stably transfected with 
GFP-tagged WT and I2.43T mutant CB1 receptor and treated with 7µM 2-AG with and 
without pre-treatment with 200 ng/ml PTX. Each data point represents the mean ± S.E 
(error bars) of at least three independent experiments. 
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Figure 7. I2.43A Mutant Exhibits β-Arrestin Biased Signaling Paradigm. A) dose 
response curves 15minutes following treatment by 2-AG for the WT and I2.43A mutant 
CB1 receptor with pEC50 values of 5.42 ± 0.10 and 5.23 ± 0.09 respectively (pEC50 
values determined by non-linear regression using least squares fitting analysis, n=3). B) 
HEK293 cells expressing GFP-hCB1 treated with 6µM 2-AG. Statistical significance of 
the differences was assessed using two-way analysis of variance and Bonferroni’s test., *, 
p _ 0.03. C) In-cell western blots for HEK293 cells stably transfected with GFP-tagged 
WT and I2.43A mutant CB1 receptor before and after treatment with 2-AG. D) In-cell 
western blots for HEK293 cells stably transfected with GFP-tagged WT and I2.43A 
mutant CB1 receptor and treated with 6µM 2-AG with and without pre-treatment with 
200 ng/ml PTX. Each data point represents the mean ± S.E (error bars) of at least three 
independent experiments. 
 
 
The S7.57E mutant exhibits β-arrestin biased signaling paradigm:  The amino 
acid residue at 7.57 resides at the elbow between TMH7 and H8. This residue does not 
show high conservation among class A GPCRs, but the S7.57E mutant was aimed to 
stabilize the highly conserved Y7.53 in trans conformation (see Discussion). 
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Dose response curves at the WT and S7.57E mutant receptors were determined 15 
minutes after treatment with 2-AG. pEC50 value for 2-AG at the mutant receptor was 
comparable to the WT receptor, with pEC50 values 5.68 ± 0.25, and 5.30 ± 0.13 
respectively. The pERK signal for the S7.57E mutant pretreated with PTX was not 
statistically significant from the mutant receptors without PTX treatment at all time 
points, suggesting that the generated pERK signal from the mutant is through β-arrestin 
only. At 10 minutes, the mutant shows a statistically lower pERK signal compared to the 
WT receptor, and no statistical difference was observed between the WT and the mutant 
receptor pretreated with PTX. The results suggest that the mutant receptor is biased 
towards the β-arrestin signaling pathway, yet it does not show robust 10 minutes or 15 
minutes signal as for the I2.43T mutant. A possible explanation of the reduced efficacy of 
the mutant would be the presence of a lysine residue at the IC1 loop that might be 
interacting with this glutamate residue and holding TMH7/H8 elbow region in position, 
or that the glutamate residue increases the bulk at the opening at TMH7 resulting in steric 
clash with the arrestin upon binding. 
 
 
 
 
31 
 
Figure 8. S7.57E Mutant Exhibits β-Arrestin Biased Signaling Paradigm. A) dose 
response curves 15minutes following treatment by 2-AG for the WT and S7.57E mutant 
CB1 receptor with pEC50 values of 5.68 ± 0.25 and 5.30 ± 0.13 respectively (pEC50 
values determined by non-linear regression using least squares fitting analysis, n=4). B) 
HEK293 cells expressing GFP-hCB1 treated with 7µM 2-AG. Statistical significance of 
the differences was assessed using two-way analysis of variance and Bonferroni’s test., 
*/#, p _ 0.03. C) In-cell western blots for HEK293 cells stably transfected with GFP-
tagged WT and S7.57E mutant CB1 receptor before and after treatment with 2-AG. D) 
In-cell western blots for HEK293 cells stably transfected with GFP-tagged WT and 
S7.57E mutant CB1 receptor and treated with 7µM 2-AG with and without pre-treatment 
with 200 ng/ml PTX. Each data point represents the mean ± S.E (error bars) of at least 
three independent experiments.
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Discussion 
Initial reports of G-protein independent, β-arrestin dependent pERK signal where 
reported on the β2-adrenergic receptor (β2AR). Treatment of HEK293 cells expressing a 
mutant β2-adrenergic receptor (β2ARTYY) with Isoproterenol (non-biased agonist), 
resulted in a pERK signal that was insensitive to H-89 (PKA inhibitor), while 
significantly dropped by knockdown of either β-arestin 1 or 2 using small interfering 
RNA, this β-arrestin dependent pERK signal was late (peak 5-10 min) compared to the 
G-protein dependent pERK signal (peak at 2-3 min).[69] Later, carvedilol, which have 
been known as β2AR antagonist, was reported to activate the ERK1/2 in a β -arrestin 
dependent pathway, thus acting as a β -arrestin biased ligand.[75]  
Experimental evidence of biased signaling through the CB1 receptor has been 
reported using the allosteric modulator, ORG-27569, which has been shown to act as a 
biased β-arestin-1 agonist.[18, 76, 77] In knock-out studies, deletion of β-arrestin 1 and 2 
in mice resulted in different efficacies of CB1 receptor agonists in anti-nociception and 
lowering body temperature suggestive of agonist-specific regulation of β-arrestin 1 / 2 
[59, 78]. In addition, a recent in vitro study in neuronal models of Huntington Disease 
(HD) shows that enhancing the Gαi/o and Gβ/γ biased signaling maybe therapeutically 
beneficial in HD by normalizing CB1 receptor levels and improving cell viability while 
agonists that displayed β-arrestin-1 bias resulted in reduced CB1 receptor levels and 
might be detrimental to CB1 signaling, particularly in HD where CB1 levels are already 
reduced [72].  
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Rational behind mutations: an overview of reported conformational changes 
upon class A GPCRs activation: Multiple efforts in the field of GPCRs have been 
directed to understand structural changes in the protein upon ligand binding. As a result, 
the two-state model of receptor activation has been challenged, by showing that different 
ligands can induce distinct patterns of conformational changes in the receptor.  At the 
CB1 receptor; an in situ reconstitution technique to directly measure G protein 
activation,[79] and a Plasmon Wave-guide Resonance (PWR) spectroscopy study,[80] 
demonstrated that different agonists induce different conformational changes in CB1 
resulting in preferential activation of different G-proteins. In addition, a quantitative 
mass-spectrometry analysis that measures site-specific conformational changes in the β2-
adrenergic receptor using nine different ligands, has shown distinct patterns of 
conformational changes produced during receptor activation.[81] 
However, class A GPCRs still share a common activation mechanism. Different 
studies using mutations and spectroscopic techniques such as NMR, EPR, MS, and X-ray 
crystallography, have shown a unique pattern of conformational changes that accompany 
receptor activation via the G-protein signaling pathway that is distinct from those 
accompanying the β-arrestin signaling pathway (see Fig. 9). 
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Figure 9. Cartoon Representation of Conformational Changes at the IC Domain of 
Class A GPCRs. Inactive state (Up): the bundle is closed at the IC domain of the 
receptor. G-protein-coupling active state conformation (Right): activation includes a 
movement of the IC domain of TMH6 away from the receptor resulting in an opening in 
the TMH3/5/6 region. β-arrestin-coupling active state conformation (Left): activation 
includes an opening between TMH7/1/2 region. 
 
 
G-protein coupling active state conformational changes: Available active state 
crystal structures and biophysical studies revealed a set of concerted conformational 
changes that result in an opening at the intracellular domain of the receptor between 
TMH 3, 5, and 6 allowing the coupling to the G-protein.[82] Those changes involve: I) A 
counterclockwise rotation (EC view) of the intracellular domain of TMH6, and flexing in 
TMH6 CWxP hinge region resulting in outward movement of IC end of TMH6 away 
from TMH3, this will break an ionic interaction between R3.50 and D/E6.30 at the IC 
ends of TMH3/6.[83-85] Flexing in the CWxP motif, is produced by ligand binding that 
alters the dihedrals of “toggle switch” residues. For CB1, these are F3.36 and W6.48 (part 
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of the CWxP motif). The change produced is a shift in W6.48’s χ1 dihedral from g+ to 
trans upon activation.[86, 87] II) Packing of TMH7 against TMH3: conserved Y7.53 
changes its χ2 dihedral by -60°and interacts with R3.50 in its active rotameric state and 
with Y5.58 leading to a conserved orientation of R3.50, Y7.53, and Y5.58 in the active 
state receptors compared to their inactive states.[82] III) An amino acid residue at TMH3 
(at 3.46) breaks a contact with TMH6 (at 6.37), and forms a contact with Y7.53.[88] IV) 
Rotational movement of TMH3 towards TMH2 that allows direct hydrogen-bond 
interaction between S3.39 and D2.50 compared to the inactive state in which those 
residues are bridged by either a water molecule or a sodium ion.[89] V) A break in the 
hydrophobic layer at the intracellular domain of the receptor.[90] (see Fig. 10,11) 
Within the previously mentioned conformational changes, it can be noticed that 
the packing of TMH7 between TMH6 and TMH3 and the triad interaction of 
Y7.53/R3.50/Y5.58 stabilize TMH6 in its active state's outward conformation. Most 
importantly, the rotation of TMH3 towards TMH2 seems to be the most crucial in the 
activation process. During this rotation, a conserved non-polar amino acid residue 
(L3.43) is translated towards TMH2, which relieves a steric hindrance that would occur 
between Y7.53 and L3.43 upon activation. In consensus with that, mutating L3.43 to 
Alanine at the CB1 receptor resulted in highly constitutively active receptor.[91] This can 
be explained by the absence of a bulky residue, thus allowing the movement of Y7.53 
towards TMH3 without steric hindrance (see Table 2, and Fig. 12). 
It should be mentioned that the active state crystal structure of the CB1 receptor 
concur with previously mentioned conformational changes upon G-protein coupling. 
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Interestingly, Site-directed florescence labeling (SDFL) study using a minimal cysteine 
receptor with a truncated N terminus (Δ87) and truncated C terminus (Δ417) has shown 
that CP-55940-induced changes in Bimane fluorescence occurs faster in the Hx8 attached 
probe (at L7.60) compared to that attached to TMH6 (at A6.34), this may suggest that the 
inward movement of TMH7/Hx8 precedes the outward movement of TMH6 in G-protein 
signaling.[92] 
 
 
Figure 10. Conserved Conformational Changes at the IC Domain of Class A GPCRs 
Upon Receptor Activation (G-Protein Coupling State). An IC view showing 
transmembrane helices rearrangements, and conformational changes in conserved 
residues; Y7.53, Y 5.58, and R3.50 (shown as sticks) in crystal structures of the CB1 
receptor (PDB IDs: 5U09[16], 5XRA[86]): comparing the R*G state (Purple) vs the R 
state (yellow green); activation includes an inward movement of IC domain of TMH7, 
allowing Y7.53 to reposition between TMH3 and TMH6 stabilizing the outward 
movement of TMH6 and interacting with R3.50 and Y5.58. This is accompanied by 
rotamer change of the χ2 and χ3 dihedrals to trans, while the χ2 dihedral of Y7.53 is 
shifted by -60 degrees. Black arrows show the direction of TMH6/7 upon activation, 
while red arrows indicate the conformational changes in R3.50 and Y7.53. 
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Figure 11. G-protein Coupling Active State of Class A GPCRs Exhibits Rotation of 
TMH3 Towards TMH2. A side view from the crystal structures of CB1 receptor in its 
inactive (Left) and active (Right) states. (TMH6 and TMH7 were removed for 
clarification). TMH2 in orange and TMH3 in yellow. The distance between the Cα atoms 
of D2.50 and S3.39 is resduced by 1.8 Å and the rotation allows direct H-bond interaction 
between both residues’ side chains.  
 
 
Table 2. Shorter Distances Between TMH3 and TMH2 Upon Receptor Activation. A 
conserved axial rotation of TMH3 towards TMH 2 in class A GPCRs results in a decrease 
in the Cα distance between D2.50/S3.39 and between L2.46/L3.43. Measures were 
obtained from crystal structures of the CB1 receptor (PDB ID: 5U09[16], 5XRA[86]), 
Adenosine receptor A2AR (PDB ID: 4EIY[93], 5G53[94]), the β2AR (PDB ID: 2RH1[95], 
3SN6[85]), μ-opioid receptor (PDB ID: 5G53[96], 4DKL[97]), and the muscarinic 
receptor (PDB ID: 3UON[98], 4MQS[99]). 
 
Receptor D2.50-S3.39 L2.46-L3.43 
CB1 1.8 1.3 
A2AR 2.3 1.6 
β2AR 0.8 0.5 
μOR 1.9 1.1 
M2 1.5 1.3 
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Figure 12. The Role of L3.43 in Stabilizing Inactive State Conformation. Intracellular 
view of the inactive state crystal structure of the CB1 receptor (PDB ID: 5U09). 
Conformational change in TMH7 and Y7.53 that lead to G-protein coupling requires the 
rotation of TMH3 towards TMH2. Without this rotation, L3.43 would sterically hinder 
TMH7 transition. 
 
 
β-arrestin coupling active state conformational changes: Few features are yet 
known that describe the conformational changes associated with the G-protein 
independent β-arrestin coupling to the receptor. Reported changes involve a movement of 
the IC domain at TMH7/Hx8 elbow region while preserving the TMH3/6 ionic lock. 
At the CB1 receptor, Fay and Farrens demonstrated differences in the CB1 
structure stabilized by ORG-27569 (biased β-arrestin-1 ligand) from that stabilized by an 
orthosteric agonist that activates the G-protein pathway; specifically, TMH6 movement 
was blocked while TMH7/Hx8 movement was enhanced upon ORG- 27569 binding.[92] 
Other studies on the arginine-vasopressin receptor and the β2AR have shown a different 
movement of TMH7 in receptors treated with β-arrestin biased ligands compared to a 
movement of TMH6 in receptors treated with G-protein activating ligands.[100, 101]  
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MD simulations at the Reggio’s Lab were used to investigate the binding of 
ORG-27569 to the CB1 receptor (Unpublished). In this simulation, the IC domain of 
TMH7 and H8 move away from TMH6 resulting in an opening at the IC domain of the 
receptor, and the Y7.53 was noticed to form stable trans χ1 dihedral conformation 
throughout the simulation (see Fig. 13). Interestingly, a similar trans χ1 dihedral 
conformation of Y7.53 is observed in a recently published crystal structure of the 5-HT2B 
receptor bound to the β-arrestin biased agonist LSD.[102] This change in Y7.53 
conformation might suggest a role of Y7.53 in the interaction with the β-arrestin. 
 
 
Figure 13. Conformation of Y7.53 in β-Arrestin Active State Conformation at the 
CB1 Receptor. An intracellular view of the CB1 receptor from a MD simulation with 
ORG-27569. The figure shows that Y7.53 adopts a trans χ1 dihedral. The I2.43 and the 
S7.57 are also shown.  
 
 
Role of water-mediated hydrogen bond network in regulating GPCR function: 
The availability of high resolution crystal structures revealed a binding site for sodium 
ion inside class A GPCRs, in which the sodium ion is coordinated mainly with the highly 
conserved residue; D2.50. This ion has long been known to act as an allosteric modulator 
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of many GPCRs. These structures reveal also a water-mediated hydrogen bond network 
inside the sodium binding pocket, these water molecules coordinate with the sodium ion 
and interconnect other conserved polar amino acid residues surrounding the pocket; 
N1.50, S3.39, W6.48, N7.45, N/D7.49, Y7.53, N/S3.35, and S7.46 [70, 93, 103-105]. 
While the inactive state crystal structure of the CB1 does not show this sodium ion, two 
different studies on the CB1 receptor suggested a role of the sodium in the stabilization of 
the inactive state of the receptor.[92, 106] 
Different studies have pointed out the role of water in the activation of the 
GPCRs. [107, 108] However, a set of non-polar conserved amino acids (at positions 1.53, 
1.57, 2.43, 2.46, 3.43, 3.46, 6.37, 6.40) form a hydrophobic layer that act as a boundary 
between the hydrogen bond network and the IC domain of the receptor, preventing the 
flow of water to the IC domain, and preserving the inactive state of the receptor (see Fig. 
4, Table 3). The role of those residues and the conserved Y7.53 in controlling the flow of 
water from the sodium binding pocket to the IC domain was examined via MD 
simulations[109-112].  
According to previous discussion, it has been hypothesized that mutations that 
would either break the hydrophobic layer between TMH3/5/6, or that enhance the 
rotation of TMH3 towards TMH2, or that facilitate the packing of Y7.53 against TMH3, 
should bias the signal towards G-protein pathway. On the other hand, mutations that 
break the hydrophobic layer between TMH1/2/7, or those that enhance a trans rotameric 
state of the Y7.53, would bias the signal towards β-arrestin signaling pathway. Results 
from I2.43A/T and S7.57E mutations are in accordance with the proposed hypothesis and 
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were successful in biasing the signaling of the CB1 receptor towards the β-arrestin 
signaling pathway.  
 
Conclusions 
In the current study, the I2.43T mutant could generate an early pERK signal that is 
similar in the onset time to the G-protein dependent pERK signal in the WT receptor treated 
with 2AG. A similar result has been reported for ORG-27569 acting on the WT receptor. 
These findings show that the receptor can adopt a β-arrestin active state conformation 
directly without prior G-protein active state conformation. The change in the conformation 
of the receptor is dependent on the ligand-receptor complex and needs to be evaluated for 
each complex separately to determine the onset of the β-arrestin dependent pERK signal. 
Orthosteric CB1 receptor agonists that act as β-arrestin biased ligands are not 
available yet. The availability of β-arrestin biased mutants would provide a tool to 
investigate downstream signaling pathways via the β-arrestin and to set structure-based 
ligand designing rules to design β-arrestin biased ligands. While the resultant functional 
selectivity of the three mutants agreed with previous observations regarding G-protein vs 
β-arrestin coupling active state conformations, further studies using MD simulations 
would reveal detailed mechanism of the effect of these mutations on the receptor’s 
conformation, specifically their impact on the rotameric state of Y7.53.  
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Table 3. Conservation in Amino Acid Residues Aligning the Sodium Binding Pocket 
in Class A GPCRs. Table shows consensus residue and other possible amino acids at 
each position. Table generated from GPCRdb website for class A GPCRs from human 
species.[113, 114] 
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1 
1.50 N (98) S (1) - - - N 
1.53 V (65) A (14) L (7) T (5) S/I/F/M (8) V 
1.57 L (24) I (23) V (20) F (17) T/A/Y/S/R/M/N (14) I 
2 
2.43 L (36) I (35) V (12) M (8) F/A/S/T/Y (8) I 
2.46 L (90) M (4) I (3) T (1)  V (1) L 
2.50 D (92) N (3) E/G/H/T (4) - - D 
3 
3.39 S (72) G (11) T (8) A (3) C/E/P/Q (1) S 
3.43 L (73) I (10) V (7) M (5) T/G/F/A (4) L 
3.46 I (56) L (16) M (13) V (10) T/A/F (3) T 
6 
6.38 L (22) A (14) V (13) F (12) 
C/G/I/M/R/S/T/Y 
(37) 
V 
6.40 V (37) I (28) L (15) M (5) A/F/H/N/S/T/Y (16) L 
6.48 W (68) F (16) Y (3) G (3) A/M/Q/S/T (7) W 
7 
7.45 N (67) S (11) H (9) A (3) C/I/K/P/Q/R (8) N 
7.46 S (64) C (13) A (8) T (6) F/G/L/N/P/Q/V (8) S 
7.49 N (72) D (20) H/K/L/S/T (7) - - N 
7.53 Y (89) F (4) L (3) C (1) - Y 
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CHAPTER III 
 
TOWARDS THE REMODELLING OF THE N-TERMINAL REGION OF THE 
CANNABINOID RECEPTOR (CB1): DOCKING STUDIES AND MOLECULAR 
DYNAMICS SIMULATIONS 
 
Introduction 
Recently published crystal structures of the CB1 receptor show differences 
between the active (PDB ID: 5XR8, 5XRA[86]) and inactive states (PDB ID: 5TGZ[15], 
5U09[16]); specifically, in the N-terminus and at the extracellular domain of the receptor 
that identifies the ligand binding pocket. In the inactive state structures, the membrane 
proximal region (MPR) of the N-terminus invades the receptor binding pocket steering an 
important interaction site (K3.28) away from binding pocket.[115] This residue has been 
reported as a site of interaction with classical and non-classical cannabinoids and the 
biarylpyrazole derivatives,[116-118]  as well as being an essential interaction site with 
SR-141716A for its inverse agonist property at the CB1 receptor.[119-122] Resolved 
structures also lack an internal disulfide bridge at the N-terminus that allosterically 
modulates the binding affinity of ligands to the receptor.[123]  
The CB1 receptor is unique in having a relatively long (114 amino-acid residues) 
N-terminus compared to other class A GPCRs. Analysis of the amino acid sequence of the 
MPR of the amino terminus reveals a high conservation in that region (see Fig. 14).
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Kendall’s lab reported no effect on prolylglycine insertion in the N-terminus (at 
A73, L86, and E100) of hCB1 receptor expressed in HEK 293T cells on agonist (CP-
55940) and antagonist (SR-141716A) binding.[124] In different studies, CP-55940 
binding to truncated receptor at the N-terminal region (Δ64, Δ80, Δ89, Δ103 shCB1 ) was 
comparable to the WT receptor,[123, 125] while the binding affinity of SR-141716A to 
the Δ103 shCB1 truncation mutant was higher compared to the WT with retained ability 
to inhibit basal signaling of the truncated mutant.[123] On the other hand, reduction of 
the disulfide bridge at the N-terminus C98/C107 reduces CP-55940 efficacy in GTPγS 
binding assay.[123] 
 
 
 
Figure 14. Conserved Amino Acid Residues in the MPR of the N-Terminus in CB1 
Receptor. The most conserved residues are colored in light green. Those with 100% 
conservation among the species analyzed are bolded. The two cysteine residues that form 
a disulfide bridge are colored in red. Eleven species were used for this graph; Human 
(Homo sapiens), Chimpanzee (Pan troglodytes), Rhesus macaque (Macaca mulatta), 
Mouse (Mus musculus), Rat (Rattus norvegicus), Cat (Felis catus), Bovine (Bos Taurus), 
Zebra finch (Taeniopygia guttate), African clawed frog (Xenopus laevis), Edible frog 
(Pelophylax esculentus), Roughskin newt (Taricha granulosa). Data obtained from 
UniProt.org.[126] 
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The compound [5-(4-chlorophenyl)-N-[(1R,2R)-2-hydroxycyclohexyl]-6-(2- 
methoxyethoxy)-3-pyridinecarboxamide] (14h), has been described previously as a 
peripherally selective, high affinity CB1 receptor antagonist[127]. However, this 
compound has been shown to have higher affinity for the hCB1 receptor compared to 
rodents CB1 receptor[128]. Mutational, and modelling studies from the Kunos lab 
identified an N-terminal residue (M106 in rodent CB1 compared to I105 in human CB1) 
as the determinant of the species differential affinity of this compound at the CB1 
receptor, a mutation that did not affect SR-141716A binding to the receptor[128] (see Fig. 
14). 
We sought to dock 14h inside the inactive state structure of the CB1 receptor in 
the effort to model the MPR of the N-terminus. The modeling of the N-terminus will be 
guided by 14h’s dock, and with the I105M mutation data that affects 14h’s affinity. In 
this work, we report a molecular dynamics (MD) simulation of 14h in a fully hydrated 1-
palmitoyl-2-oleoyl-phosphatidylcholine (POPC) bilayer, as well as a docking study 
of 14h in an inactive state CB1 receptor model based on the CB1 crystal structure (PDB 
ID: 5U09[16]). Finally, stability of the CB1 receptor with a modeled N-terminus and in 
complex with 14h was monitored in a MD simulation. 
 
  
Figure 15. Chemical Structure of 14h.  
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Methods 
Quantum mechanical potential energy scan (QM-PES) for 14h dihedrals: 
Crystal structure for 14h was reported previously,[128] and coordinates were downloaded 
from Cambridge Crystallographic Data Centre (www.ccdc.cam.ac.uk). Using the crystal 
structure geometry, energy scans for all dihedrals was performed for 14h using ab initio 
Hartree-Fock calculations in vacuum at the 6-31G* level as encoded in the Spartan 08 
molecular modeling program (Wavefunction, Inc., Irvine, CA).  With this, a 360° rotation 
on each rotatable bond is applied in 10° increments. After rotating each dihedral, single 
point energy was calculated for each generated conformer. Geometries with local minima 
were then used as initial geometries for the rotation of subsequent dihedrals. In case of 
adjacent dihedrals with harmonized effect on the energy of generated conformers, both 
dihedrals were rotated, and energy surface was plotted to determine the local energy 
minima of 14h at those dihedrals.  
Preparation of the CB1 receptor bundle for docking and MD simulations: 
CB1 crystal structure coordinates were downloaded from the Protein Data Bank (PDB 
ID: 5U09[16]). The bundle was prepared for MD simulation using Maestro (Schrödinger 
Release 2016-4: Maestro, Schrödinger, LLC, New York, NY, 2016), missing IC-3 loop 
and C-termini were added (using Modeller [129, 130]) according to the following: fusion 
protein at the IC-3 loop was removed and the loop was built according to previous NMR 
study of this loop region in micelle, which reported three helical regions in the loop; two 
helical regions extend from TMH5 (L298 –R307), and TMH6 (Q334 – L345), and a third 
helical domain terminal to TMH5 (I309 – S316).[131] Crystallized ligand and lipids were 
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deleted, protein preparation wizard implemented in Maestro was used to add hydrogen 
atoms, connect disulfide bridge, assign bond orders, eliminate crystallographic water 
molecules, and cap free residues. Prime module in Maestro was used to add missing side 
chains.[132, 133] The thermostabilizing T210A mutation was mutated back to the WT, 
and the Glutamate residue at TMH1 (E1.49) which faces lipids was protonated according 
to pKa calculations and to a previous report.[18] Alpha helical domain of TMH8 was 
built up to G417 according to previous reports that show that a CB1 receptor with 
truncation at this point retain cell surface expression and signaling [50, 92, 134-136], and 
a Palmitoyl group was added to C415.[137] As part of the internal water-mediated 
hydrogen bond network described in the literature, high-resolution crystal structures 
revealed consistency in the location of certain water molecules.[70, 93, 103-105] These 
locations are a) at TMH6/7 interface making H-bond with backbone carbonyls of C6.47 
and x7.38, b) at TMH6/7 interface making a H-bond with N7.45/N7.49 and the backbone 
carbonyl of x6.40, c) at TMH1/7 interface making a H-bond between backbone carbonyls 
of x7.47 and x1.45, d) in between W6.48 and N7.49. Water molecules at those locations 
were added to the structure except the one at TMH1/7 interface due to the presence of 
E1.49. In addition, a sodium ion was placed between D2.50 and S3.39. 
Minimization of the bundle: an initial minimization of the hydrogens and water 
molecules inside the bundle was first done using OPLS3 force field (applying an 8.0 Å 
extended nonbonded cutoff, a 20.0 Å electrostatic cutoff, and a 4.0 Å hydrogen bond 
cutoff) in a distant-dependent dielectric constant environment.[15] Then the bundle was 
minimized in an implicit membrane using Prime which allows the minimization of the 
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whole bundle by treating the transmembrane region at a low dielectric constant 
corresponding to the hydrophobic region of the membrane, while the loops being treated 
at high dielectric constant corresponding to water.[132] With that, the bundle is first 
oriented in the membrane using OPM data base,[138] and then minimized in 3 iterations 
of 65 steps per iteration using OPLS3 force field and applying automatic minimization 
which uses Conjugate Gradient minimization at large RMSD gradients and switches to 
Truncated Newton method at low gradients.  
Prime induced fit docking of 14h in the CB1 receptor: Results from 
conformational analysis of 14h were rigidly docked in the CB1 receptor bundle using 
Prime-induced fit docking[139] and applying the OPLS3 force field for the treatment of 
the ligand and the receptor. Centroid of residues S1.39 (123), F2.64 (177), V3.32 (196), 
F268, W5.43 (279), T5.47 (283), W6.48 (356), Y7.53 (397) was used to define the grid 
box size and center. Receptor and ligand VDW were rescaled to 1.0 with a maximum 
number of poses being 20. Residues within 5.0 Å of ligand poses were refined allowing 
optimization of protein side chains. Calculations were carried in an implicit membrane as 
explained previously. 
Modeling of the N-terminus: For the crystal structure, a disulfide bridge was 
added and the N-terminus was modeled from S88 to E100 using Modeller. Remodeling of 
the N-terminus was done using Prime Loop refinement module in Maestro which was 
used to predict a sample of conformations of the N-terminal region (S88 – P113). The 
location of I105 was restricted within 2Å of its original crystal structure coordinates to fit 
I105M mutation data.[133] 
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MD simulations: Isobaric-isothermic (NPT) simulations were performed using 
the GPU-enabled AMBER16 molecular dynamics package [Case et al., Amber 2016], 
applying the CHARMM36m[140] and CHARMM36[141] force fields for proteins and 
lipids respectively, and a stream file that contains 14h parameters. Initial 5000 steps of 
restrained minimization were carried using the default CHARMM-GUI protocol for 
AMBER[142], equilibration and production runs were ran at a temperature of 310K 
(controlled with Langevin thermostat) and 1atm pressure (controlled with Monte Carlo 
barostat). Periodic boundary conditions (PBC) were employed. Non-bonded cutoff 
distance was set to 12 Å, and long-range electrostatic interactions beyond this cutoff were 
calculated using the Particle Mesh Ewald (PME) method, and bond lengths to hydrogen 
atoms were constrained using SHAKE algorithm.  
MD simulation for 14h in a POPC bilayer: Two independent all atom MD 
simulations were performed for 14h in a POPC bilayer. The simulations were prepared 
and run like previously described MD simulation for SR-141716A in a POPC bilayer 
(Chapter IV) with different number of lipids in each leaflet which is 83, in addition, only 
one molecule of 14h was added to the water phase in each simulation. Topology and 
parameter files for 14h were obtained directly from CGenFF.ParamChem.org server, and 
were evaluated for the reproduction of crystal structure geometries equilibrated at MP2/6-
31G* level of theory, and for the reproduction of dihedrals potential energy scans during 
the MD simulation. Lipid order parameters and mass density distributions were 
calculated using LOOS [143],  Tcl tools in VMD [144] were used to calculate area per 
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lipid, H-bond interaction of 14h with the lipid bilayer, and dihedral angles probability 
distributions.  
MD simulation for the CB1 receptor-14h complex in a POPC bilayer: CB1 
receptor bundle prepared for the MD simulation as described earlier was fed into the 
CHARMM-GUI online membrane building tool.[145] Simulation cell 
(80 Å × 80 Å × 124 Å, with the z-axis being normal to the plane of the bilayer) contained 
~75 and 76 POPC molecules on the upper and lower leaflets respectively. The membrane 
was solvated with TIP3 water (thickness of 18 Å on both sides of the protein) and 0.15 M 
NaCl. Standard CHARMM-GUI minimization and equilibration steps were performed 
followed by more than 100ns production runs.[146] 
MD simulations were used to investigate interaction dynamics of 14h with the 
CB1 receptor at the transmembrane portal, and inside the CB1 receptor binding pocket. 
To study interaction dynamics at the transmembrane portal, three MD simulations were 
run where a single molecule of 14h was placed at the transmembrane portal between 
TMH1/TMH7 and at different orientations. To study the interaction dynamics of 14h 
inside the receptor binding pocket, two different 100ns and 200ns simulations were run, 
where 14h was docked inside the CB1 crystal structure, or inside the CB1 receptor 
crystal structure with modelled N-terminus, respectively. 
Tools implemented in VMD [144] were used to measure hydrogen bond 
interaction of the ligand with the receptor, RMSD of the transmembrane region of the 
receptor, salt bridge distances of DRY/D6.30 ionic lock, side-chain dihedral changes, and   
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to calculate the distance between the IC ends between TMH3/TMH6 (Cα distances 
between R3.50 and D 6.30), and TMH2/TMH7 (Cα distances between Y7.53 and I2.43). 
 
Results 
MD simulation of 14h in POPC bilayer: To study the dynamics of 14h in a lipid 
bilayer, two independent 300ns all atom MD simulations were run. In both simulations, 
one 14h molecule was added to the bulk water, and partitioning into the lipid phase was 
achieved within the first 100ns of each simulation (see Fig. 16). It could be noticed that 
14h moves from the bulk water into the lipid bilayer by first forming H-bond interaction 
with the phospholipid headgroups via its cyclohexanol ring. This initial interaction drives 
the molecule into the lipid in which 14h would maintain its H-bond interaction with the 
phospholipid headgroups throughout the simulation. 
Area per lipid and lipid order parameters were measured for the whole period of 
the simulations. Average area per lipid for both simulations was 65 Å2 (RMSD = 1.1 Å2) 
in agreement with experimental values[147] (see Fig 17). Palmitoyl (sn1), and oleoyl 
(sn2) acyl chains order parameters (SCD) were also calculated for both simulations and 
were comparable to experimentally determined order parameters for POPC at 300K[148] 
(See Fig. 18). (Calculation of lipid order parameters is briefly discussed in Chapter IV). 
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Figure 16. Snapshots from 300ns MD Simulation of 14h in POPC Bilayer. The figure 
shows the partitioning of 14h from bulk water into the POPC bilayer. The partitioning of 
14h into the lipid bilayer starts with an interaction of the cyclohexanol ring with the head 
groups. In the bilayer, 14h rotates in different directions, while showing two main 
orientations in the bilayer: vertical (presented at the 72 ns), or horizontal (presented at the 
94 ns), with the cyclohexanol ring always near the lipid headgroups.  Color Key: 
Phosphorus (Ochre spheres), Choline Nitrogen (Blue spheres), lipid tails (Silver thin 
tubes) (hydrogen atoms were not displayed). For 14h: Carbons (Yellow), Oxygen atoms 
(Red), Chlorine (yellow green), Hydrogens (White), and Nitrogen (Blue). 
 
 
 
Figure 17. Area per Lipid Calculated for the whole 300ns of both MD Simulations of 
14h in POPC Bilayer. The average area per lipid is ~ 65 Å2  
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Figure 18. Lipid Order Parameters from MD Simulations of 14h in POPC Bilayer. 
Calculated lipid order parameters for the sn1 (Palmitoyl) and the sn2 (Oleoyl) chains of 
POPC. Results from MD simulations of 14h in POPC bilayer (Red), and NMR 
experimental values[148] (Black). Error bars represent standard error. NMR reference 
values were extracted by digitizing plotted graph in the reference paper[148]. 
 
 
Density distribution: Density distributions for the bilayer components as well as 
for 14h and 14h subset groups were calculated and determined for the last 200 ns of each 
simulation. During both simulations, 14h was retained beneath the phospholipid head 
groups, this is due to the permanent H-bond interaction of the cyclohexanol group with 
the lipid head groups and interfacial water molecules (see Fig. 19, and Table 4). The 
molecule adopts two main orientations in the lipid bilayer; a horizontal orientation 
parallel to the lipid bilayer with its methoxyethoxy tail forming additional interactions 
with the phospholipid head groups, or vertically oriented with that tail oriented towards 
the center of the bilayer. 
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Figure 19. Mass-Density Distributions from MD Simulation of 14h in POPC Bilayer. 
The density distribution through the Z-axis (normal to the bilayer) is shown. The zero 
point on the Z-axis represents the center of the bilayer. Phospholipid bilayer components 
are shown in dotted lines. The whole 14h compound distribution is in blue line, and 14h 
subset groups are colored according to the chemical structure at the top right.  
 
 
Table 4. Hydrogen Bond Analysis of 14h in the Lipid Bilayer. last 200 ns of the 
simulation were analyzed and the percentages of the time the ligand sub-groups are 
interacting with either the phospholipid head groups or interfacial water molecules are 
listed. 
 
Interacting group % interaction time 
Pyridine 26 
Amide nitrogen 80 
Amide oxygen 23 
Hydroxyl group 98 
Tail oxygen 36 
 
 
Dihedrals probability distributions: 14h dihedrals were measured throughout the 
simulations of 14h in the lipid bilayer and compared to QM-PES to validate the quality of 
ParamChem-generated forcefield parameters for 14h (see Fig. 20). 
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Figure 20. Dihedral Probability Distribution and Energy Profiles for 14h. Probability 
dihedral distribution from the MD simulation plotted against the dihedral energy profiles 
determined at the HF/6-31G* level. The chemical structure on top shows the relevant 
dihedrals; dihedral A (C1’-N1’-C1’’’-C2’’’), dihedral B (C6-C5-C1’’-C2’’), dihedral C 
(C6-O-C1’’’’-C2’’’’), and dihedral D (C2-C3-C1’-N2’). For Dihedral C; the blue line 
represents the energy profile for that dihedral at dihedral CC value of 53°, while the red 
line represents the dihedral energy profile at dihedral CC value of -67°. 
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For the dihedral between the amide group and the cyclohexanol ring, gas phase 
minimal energy determined at the HF/6-31G* level of theory is at ~ 80° corresponding to 
the formation of intramolecular hydrogen bond between the hydroxyl group and the 
amide oxygen, this minimum was not prevalent during the MD simulation due to the 
solvation effect in the bilayer. It can be seen also that a high energy barrier is located at ~ 
20° due to the steric clash between the hydroxyl and the amide oxygen at that dihedral 
value. In addition, the dihedral angle between the amide and the pyridine ring shows local 
minima at ~ ±40° determined from QM calculations, these local minima were not 
populated in the MD simulation and were shifted to the 0° due to the nature of the energy 
force field function which uses a cosine term in the treatment of dihedral energies. 
However, low energy barrier for that dihedral allows cis-trans isomerization during the 
simulation. The dihedral probability distribution for the bond between the chlorophenyl 
ring and the pyridine is consistent with the QM-PES. Finally, the 2-methoxyethoxy tail 
dihedrals were also determined during the simulation and were consistent with QM-PES.  
It is worth mentioning that the crystal structures of 14h show that the ligand forms 
intermolecular H-bond that involves the amide group of adjacent compounds. Those 
structures show also a preferential rotamer of the amide oxygen to be in trans 
conformation with the lone pair of electrons from the pyridine nitrogen even though the 
energy barrier between the two conformations is relatively low and energy optimization 
of both conformers at the HF level of theory results in a low relative energy between the 
two conformers (~0.1 Kcal/mol), (see Fig. 21). 
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Figure 21. 14h Crystal Structures’ Geometry. Structures show trans planar amide 
which is ~30 degrees rotated from the plane of the pyridine ring, the chlorophenyl ring is 
rotated ~35° from plane of pyridine, and no-intramolecular H-bond present between the 
cyclohexanol and the amide oxygen (satisfied in the crystal structure by inert-molecular 
H-bond between amide nitrogen of one molecule and the carboxamide oxygen from 
adjacent molecule). Color code: Carbons (Yellow), Oxygen atoms (Red), Chlorine 
(yellow green), Hydrogens (White). 
 
 
MD simulations for the CB1 receptor-14h complexes in a POPC bilayer: 
Initial interaction of 14h with the CB1 receptor: The CB1 receptor inactive state 
crystal structures show a transmembrane portal between TMH1 and TMH7 for CB1 
receptor antagonists.[15, 16] To study the initial interaction of 14h with the CB1 receptor, 
and to investigate the favored orientation of the ligand at the transmembrane portal, three 
MD simulations were run where one 14h molecule was placed next to the portal and at 
different orientations. In all three simulations, 14h rotated so that the chlorophenyl ring 
would insert into a groove in the CB1 receptor between TMH1 and TMH7. This groove 
was aligned by residues I1.35, L1.38, M7.40, and L7.43. On the other hand, the 
cyclohexanol ring formed intermittent hydrogen bond interaction with the lipid 
headgroups and E1.31 on top of TMH1 (see Fig. 22). A frame (~46ns from one of the 
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simulations) where 14h was placing its chlorophenyl ring deep in the groove was used to 
run two spawns where the velocities were scrambled. At around 90 ns of the simulations, 
M7.40 and L7.44 change their χ1 dihedrals allowing the whole structure to fit between 
TMH1 and TMH7. Specifically, M7.40 changes its χ1 dihedral from g+ to trans, while 
the L7.44 fixes its χ1 dihedral in trans (see Fig. 23 and Fig. 24). At this stage, the 
cyclohexanol ring of 14h would form either a direct or an indirect (via water molecule) 
intermittent hydrogen bond interactions with the backbone of the N-terminus. 
For the sake of docking 14h inside the CB1 receptor, these simulations elucidated 
the orientation of 14h at the transmembrane portal. The simulations demonstrated that 
14h first accesses the receptor binding site with its chlorophenyl ring, while the 
methoxyethoxy tail is hanging down towards the intracellular of the receptor (see Fig. 
23). 
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Figure 22. Initial Interaction of 14h with the CB1 Receptor at the TMH1/7 Portal at 
46ns. Top) 14h places its chlorophenyl ring in a groove aligned by hydrophobic residues 
(M7.40 and L7.44 on TMH7, and I1.35 and L1.38 on TMH1). The cyclohexanol group of 
14h forms stable H-bond interactions with either the Q1.31 on top of TMH1 or with 
interfacial water molecules around TMH1. Amino acid residues are displayed in white 
licorice representation. Bottom) Opening between the two helices and the initial insertion 
of 14h into the receptor. Surface representation for all amino acid residues aligning the 
portal between TMH1 and TMH7 including the N-terminus. Color code for 14h: Carbons 
(dark Yellow), Oxygen atoms (Red), Chlorine (yellow green), Hydrogens (White). 
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Figure 23. Interaction of 14h with the CB1 Receptor at the TMH1/7 Portal at 90ns. 
Top) The chlorophenyl ring of 14h is inside the receptor and the cyclohexanol ring forms 
indirect H-bond interaction with the backbone of I105 through water molecule. The χ1 
dihedral of M7.40 is in trans to allow the chlorophenyl ring to insert between the two 
helices. Bottom) Surface representation of the residues aligning transmembrane portal 
including the N-terminus.  
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Figure 24. Conformational Changes at the TMH1/7 Portal During Initial Interaction 
of 14h with the CB1 Receptor. Top) Interhelical (Cα) distances between I1.35 and 
F7.37, and between L1.38 and M7.40. An increase in the distance between the two 
helices is observed at ~90ns of the simulation during which the whole 14h fits in between 
the two helices. Bottom) Change in the χ1 dihedral of M7.40 and L7.44 is observed at 
~90ns of the simulation (dihedral values calculated as the absolute value of the radians).  
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Docking of 14h inside the CB1 receptor: based on observations from previous 
simulations, we picked one of the results from prime-induced fit docking where the 
ligand is oriented so that the cyclohexanol is towards the extracellular side of the receptor 
and the methoxy-ethoxy tail is pointing towards the sodium binding pocket (see Fig. 
25A).  This receptor-ligand complex was run eventually in a MD simulation to monitor 
the stability of the ligand inside the CB1 receptor binding site. In the first 20 ns of the 
simulation, 14h shifts from its initial dock to place the chlorophenyl ring near W6.48, 
while the cyclohexanol ring forms intermittent H-bond interactions with S1.39 (see Fig. 
26A, B, C). This simulation was run for a total of 100 ns, and the final dock of 14h inside 
the receptor shows that the position of the I105 in the crystal structure fits the I105M 
mutations data (see Fig. 25B). 
Finally, 14h was docked in the CB1 receptor with a modeled N-terminus. Stability 
of the CB1–14h complex was monitored through a 200ns simulation. Through the 
simulation, the cyclohexanol ring of 14h was forming stable VDW interactions with the 
I105. However, compared to the equilibrated dock of 14h inside the CB1 receptor with 
the original crystal structure N-terminus, the amide oxygen rather than the cyclohexanol 
fits next to S1.39, while the cyclohexanol ring forms additional VDW and intermittent H-
bond interactions with E106 or waters inside the binding pocket (see Fig. 26, and Fig. 
27).  
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Figure 25. Docking of 14h Inside the CB1 Receptor with the Crystal Structure’s N-
Terminus. A) initial dock showing 14h high at the binding site. B) 14h equilibrated in 
the CB1 receptor (90ns), the ligand positioned the tail towards the sodium binding pocket 
(Sodium in magenta sphere), the chlorophenyl ring is on top of W6.48, the cyclohexanol 
forms H-bond with the S1.39, and I105 (green VDW) forms VDW interaction with 14h.  
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Figure 26. Stability of 14h Docks Inside the CB1 Receptor.  For A, B, and C: yellow 
graphs are for the CB1 receptor with the original N-terminus (100ns simulations), and red 
graphs are for the CB1 receptor with the modeled N-terminus (200ns simulations). A) 
distance between the center of mass between the chlorophenyl ring of 14h and the indole 
ring of W6.48. B) distance between the center of mass between the pyridine ring in 14h 
and the phenyl ring in F2.57. C) Distance between the cyclohexanol hydroxyl oxygen 
(HO) and the side chain oxygen of S1.39. D) graph shows interatomic distances between 
(HO) in 14h and sidechain oxygens of E106, or between the amide oxygen (CO) of 14h 
and the sidechain oxygen of S1.39.
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Figure 27. Binding Site of 14h Inside the CB1 Receptor with Modeled N-Terminus 
(50ns).  
 
 
For all simulations of 14h with the CB1 receptor, RMSD of the transmembrane 
region was monitored. MD simulation with the modelled N-terminus shows stability in 
the last 100ns of the simulation compared to simulations run on the CB1 crystal structure. 
The χ1 dihedral for the toggle switch (W6.48) shows better stability at g+ in simulations 
with 14h docked inside the receptor. In addition, interhelical distances at the IC domain 
of the receptor indicate stability of the bundles in the inactive state. It can be noticed that 
the modelled N-terminus improved the stability of the CB1 receptor in its inactive state 
compared to the original crystal structure, this can be seen in the comparably shorter 
intrahelical distances at the IC domain of the receptor especially in the last 100ns of the 
simulation (see Fig. 28).  
66 
 
Figure 28. Stability of the Inactive State of the CB1 Receptor in Complex with 14h 
During MD Simulations. CB1–14h complex at the portal (green), CB1–14h docked in 
the CB1 receptor with the crystal structure original N-terminus (yellow), and CB1–14h 
docked in the CB1 receptor with modeled N-terminus (red). A) RMSD of the 
transmembrane region. B) χ1 dihedral of W6.48, the y-axis represents the radian of 
measured dihedrals. C) interhelical distances between the Cα of R3.50 and D6.30. D) 
interhelical distances between the Cα of Y7.53 and I2.43. 
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Discussion 
 Preparation of the CB1 receptor for docking and MD simulation: Two crystal 
structures of the CB1 receptor in its inactive state have been reported in complex with 
AM6538 and Taranabant, and with resolution of 2.8 Å[15] and 2.6 Å[16] respectively. 
The later (PDB ID: 5U09) was used for the docking and the MD simulations. The CB1 
receptor construct in this crystal structure had single thermostabilizing mutation 
(T3.46A). In addition, the construct (lacking residues N-terminal to K90, and residues C-
terminal from P421) had a fusion protein at the intracellular ends of TMH5 (A301) and 
TMH6(D333). While the electronic density of residues N-terminal to E100 or C-terminal 
from F412 was not resolved, the distal region of the N-terminus (specifically F102 and 
M103) occludes the receptor binding pocket. Thus, we aimed to model the proximal 
region (S88 to P113) of the N-terminus, adding the N-terminal disulfide bridge with F102 
and M103 above the binding pocket while complying with the I105M mutation data (see 
Fig. 29).  
Placement of a sodium ion inside the CB1 receptor bundle: Different studies 
reported that sodium allosterically stabilizes the inactive state of class A GPCRs. High 
resolution crystal structures of the -opioid,[149] β1-adrenergic,[103] and the 
adenosine[150] receptors revealed a high electronic density near D2.50 which has been 
attributed to the presence of sodium ion that coordinates with D2.50, S3.39. Sodium was 
not resolved in the CB1 receptor crystal structures. However, it has been shown to lower 
the binding affinity of CP-55940 to the WT receptor and to an D2.50E, but not D2.50N 
mutant.[151] In addition, the efficacy of Org-27569 (an allosteric modulator at the CB1 
68 
receptor) in inhibiting CP-55940 induced GTPγS binding to the CB1 receptor was 
significantly enhanced suggesting an increased stability of the inactive state of the 
receptor.[92]  During the current work, we ran multiple MD simulations of the CB1 
receptor without the addition of the sodium, and water inside the bundle was monitored 
during all simulations. It was noticed that sodium maintained the number of water 
molecules inside the sodium binding pocket to the original waters added, and prevented 
an overflow of water in that area. 
 
 
Figure 29. Structure of the CB1 Receptor’s N-Terminus. A) CB1 receptor with the 
original N-terminus showing the F102 and M103 inside the binding pocket. B) CB1 
receptor with the modeled N-terminus at 120ns of the simulation, F102 and M103 were 
stable outside the binding pocket. M105 in green licorice and the disulfide bridge at the 
N-terminus in white licorice. 
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MD simulations: In the effort to model the N-terminus of the CB1 receptor, our 
strategy was to dock 14h inside the receptor and model the N-terminus guided by the 
I105M mutation data which affected 14h binding to the receptor, and with the possibility 
that 14h might have a different binding site compared to the crystallized ligands inside 
the CB1 receptor. Initial docking of 14h inside the CB1 receptor yielded different 
orientations of the ligand inside the binding pocket. To better evaluate docking results, we 
ran a MD simulation of 14h in a POPC bilayer to investigate its dynamics in the lipid 
bilayer. Results from the MD simulation show that 14h would always orient its 
cyclohexanol ring towards the phospholipid headgroup forming stable hydrogen bond 
interaction with the polar head groups or interfacial water molecules, which eliminates 
some docking results that places the cyclohexanol near the D2.50. Next step was to 
decide on whether the chlorophenyl ring, or the methoxy-ethoxy tail would insert first 
into the transmembrane portal of the CB1 receptor. This is important because it would 
better determine the orientation of 14h inside the receptor. 
The CB1 receptor inactive state crystal structures show a transmembrane portal 
between TMH1 and TMH7 for CB1 receptor’s antagonists.[15, 16] Thus, three MD 
simulation runs were done where 14h was placed near the TMH1/7 portal in three 
different orientations: with either the chlorophenyl ring or the methoxyethoxy tail 
pointing towards the portal, or with both substituents at equidistance from the portal. In 
all simulations, the molecule rotated and placed its chlorophenyl ring in a groove between 
the two helices, while the cyclohexanol ring of 14h was forming alternate H-bond 
interactions with the lipid headgroups or the top of the receptor, stabilizing the vertical 
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orientation of 14h in the lipid bilayer. Such interactions require that the chlorophenyl ring 
be at an angle with the pyridine and the cyclohexanol ring (See Fig 30). This 
conformational requirement has been studied previously using different analogues of 
14h; analogues which have wide angle between the chlorophenyl and the cyclohexanol 
rings in their lowest energy conformations resulted in drastic loss of affinity.[127] It 
should be mentioned however, that the stable interaction of 14h analogues with the lipid 
headgroups via their cyclohexanol ring dictates this requirement. SR-141716A on the 
other hand has a piperidine substituent attached to the amide with wide angle between the 
piperidine ring and the chlorophenyl ring. This compound can still bind to the receptor 
due to the free movement of SR-141716A in the lipid bilayer. 
Results from previous simulations provided insight about the orientation of the 
ligand inside the receptor. Thus, one dock from our initial docking study was picked, this 
dock fits our MD simulation data obtained so far and it places 14h high and near the 
portal so that 14h could make headway freely into its binding pocket in a MD simulation. 
In its final dock inside the receptor, 14h places its chlorophenyl ring on top of W6.48 and 
in a similar way to the Taranabant and AM6538 in the CB1 crystal structures, this 
positioning helps stabilizing the inactive rotameric state of W6.48, a conserved residue in 
class A GPCRs and has been shown to act as a toggle switch during the activation of 
these receptors where it changes its χ1 dihedral from g+ to trans during activation.[83-86] 
It could be noticed also, that 14h forms stable VDW interactions with the I105, which fits 
I105M mutation data discussed previously. According to that, and in the effort to model 
the N-terminus, the spatial location of the I105 with respect to the rest of the receptor was 
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not changed from crystal structure`s location, while residues N-terminal to I105 were 
remodeled to solve crystallization artifact that places the F102 and M103 inside the 
receptor binding pocket. Finally, stability of the interaction of 14h with the CB1 receptor 
with modified N-terminus was monitored in the last 100ns MD simulation, during which 
14h maintained its interaction with the I105, plus additional VDW and H-bond 
interactions with E106. Such interactions were not observed in the MD simulation of 14h 
with the CB1 original crystal structure, and would require experimental validation.  
 
 
Figure 30. SAR of 6-Alkoxy-5-Aryl-3-Pyridinecarboxamides.  Reported Ki values in 
hCB1 receptor against [3H]CP55940 was >7000nM for the 32a analogue compared to 5.1 
± 1.6 nM for 14h.[127] The narrow angle between the cyclohexanol and the chlorophenyl 
rings allows initial interaction with the CB1 receptor. 
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Conclusions 
The current study illuminated the initial interaction of 14h with the receptor, and 
shed a light on the differences in the structural requirements of different CB1 receptor 
antagonists based on their initial interaction with the receptor and their dynamics in the 
lipid bilayer. In addition, it provided a stable model of the N-terminus that still needs to 
be validated experimentally. 
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CHAPTER IV 
 
PARAMETERIZATION AND ALL ATOM MOLECULAR DYNAMICS 
SIMULATION OF SR141716A IN A LIPID BILAYER 
 
 
Introduction 
The biarylpyrazole, 5-(4-Chlorophenyl)-1-(2,4-dichloro-phenyl)-4-methyl-N-
(piperidin-1-yl)-1H-pyrazole-3-carboxamide (SR141716A, Rimonabant (SR)), is a potent 
and selective CB1 receptor antagonist and inverse agonist.  SR (see Fig. 31) is widely 
used in pharmacological and in binding assay experiments due to the availability of 
tritiated version. It was the first approved CB1 receptor antagonist, developed by Sanofi-
Aventis, and approved in Europe in 2006 as an anti-obesity drug, but was withdrawn two 
years later due to increased reports of suicidal ideation.[152, 153] 
The SAR of biarylpyrazoles has been extensively studied through structural 
variation, and through mutation studies at the CB1 receptor binding site.[115] The two 
inactive state crystal structures for CB1 were resolved in complex with two different 
antagonists; AM6538 and Taranabant.[15, 16] However, mutation data at the CB1 
receptor suggest that the binding site of SR is deeper inside the binding pocket compared 
to the crystallized antagonists, and involves a hydrogen bond interaction with a lysine 
residue at the third transmembrane helix of the receptor.[19, 118-120] Running MD study 
of SR with the CB1 receptor in an explicit membrane can reveal different ligands' 
interactions with the receptor at a molecular level. In addition, understanding such an 
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interaction will aid in the design of new ligands with modified pharmacological activity 
based on the SR’s basic scaffold. 
 
 
Figure 31. Chemical Structure and Numbering of SR-141716A. 
 
 
Applying the CHARMM force field potential energy function to run all atom MD 
simulation necessitates the development of force field parameters for SR, such 
parameters have been well established and experimentally validated for biological 
molecules such as lipids and proteins [141]. This work describes the parameterization for 
SR, including evaluation of the internal (Bonded) and external (non-bonded) parameters, 
and two independent 300ns all atom MD simulation of SR in a fully hydrated POPC 
bilayer. 
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Methods 
The Class I additive CHARMM potential energy function is given in eq. (1) [154]. 
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The internal (bonded) part of the equation includes potential energy functions for 
bonds (b), angles (), Urey-Bradley (b1-3), dihedrals (), and improper dihedrals (). 
Subscript zero corresponds to the equilibrium value for each, and the K’s are the 
corresponding force constants. The sinusoidal dihedral energy term also incorporates 
periodicity (n) and phase shift (). External (nonbonded) energy terms include Lennard-
Jones 6-12 potential, and Coulombic potential for electrostatic interactions. In the 
nonbonded energy terms; εij is the well depth calculated as the geometric mean ( 𝑖𝑗 =
 √ 𝑖 𝑗  ), Rmin,ij is the arithmetic mean (𝑅𝑚𝑖𝑛,𝑖𝑗 =  (𝑟𝑚𝑖𝑛.𝑖 + 𝑟𝑚𝑖𝑛,𝑗)/2), qi, qj are the partial 
atomic charges, and (∈) is the dielectric constant which is set to 1 corresponding to 
vacuum and in calculations that incorporate explicit solvent. 
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Parameterization: 
Target data: Crystal structures for SR were previously published [155], 
coordinates were obtained from Cambridge Crystallographic Data Centre 
(www.ccdc.cam.ac.uk/data request/cif). MP2/6-31G* level of theory was used to obtain 
target bond lengths, angles, and dihedrals by optimizing crystal structures’ geometries in 
vacuum, as well as to generate quantum mechanical potential energy scans (QM PES) for 
missing bond lengths, angles and dihedrals using Spartan 08 molecular modeling 
program (Wavefunction, Inc., Irvine, CA [156]). 
Initial charges, atom typing, and initial guess parameters for SR: A stream file 
used as a wild card for SR was obtained from CGenFF.ParamChem.org server; this 
stream file contains SR`s topology with estimated charges, Lennard-Jones (LJ) 
parameters, as well as the initial guess parameters for missing bond lengths, angles and 
dihedrals. LJ parameters for new atom types were copied from ParamChem-generated 
atom types. 
Charge optimization: Charges for all molecular fragments were directly obtained 
from CGenFF except for molecular fragment (1). A stream file that describes the 
topology of molecular fragment 1 was downloaded from ParamChem website. Charges 
for all atoms in fragment 1 except the aliphatic hydrogens (which were set to +0.09 as 
recommended) were optimized to reproduce scaled QM interaction energies and 
distances between the model compound in its MP2/6-31G(d) optimized trans geometry (a 
geometry like the N-(piperidin-1-yl)-carboxamide moiety in SR global minima) and 
individual water molecules. To do that, a CHARMM script available in the CHARMM 
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parameterization tutorial was modified and used to place a TIP3P water molecule to form 
a linear hydrogen bond with each hydrogen bonding donor or acceptor atom in the model 
compound. Interaction distances between the model compound and individual water 
molecules were then optimized at the HF/6-31G* level in Jaguar [157] by performing 
rigid coordinate scan in which all other degrees of freedom are fixed. Resulting water 
interaction energies (calculated as EInteraction = EComplex – ESR -ETIP3) were scaled by a 
factor 1.16 as recommended and used as target data for charges optimization. Charges for 
the whole SR were then calculated by removing atoms at which molecular fragments will 
be linked and adding their charges to their parent heavy atoms.  
Bond-angle-dihedral optimization: Coordinates generated from QM PES were 
used as input geometries to generate CHARMM PES.  Coordinates of interest were fixed, 
and other degrees of freedom could minimize in CHARMM while setting the 
correspondent force constant for bonds, angles, or dihedrals to zero in the stream file. 
Resulting energy profiles were then plotted against QM profiles, and parameters were 
adjusted until generated CHARMM PES fit the MP2-generated PES.  
MD simulation: Two independent all atom MD simulations were performed for 
SR in a POPC bilayer. The simulation cell (73x73x79 Å3, Z axis normal to the plane of 
the bilayer) was built using the freely available CHARMM-GUI input generator.[142] 
Each leaflet contained 81 POPC molecules hydrated with a layer of TIP3 water (22.5 Å 
thickness) above and below the lipid bilayer and including sodium chloride ions (0.15 
M). In simulation I, three SR molecules were added randomly to each leaflet of the lipid 
bilayer by replacement method, and generated input file was checked for lipid penetration 
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into SR rings. While in simulation II, three SR molecules were added to the water layer 
at each side of the leaflet, and clashing waters or ions were removed while maintaining 
the neutrality of the system. Standard CHARMM-GUI minimization and equilibration 
steps were performed followed by 300ns, and 400ns production runs for simulation I and 
II respectively.[146]  Isobaric-isothermic (NPT) simulations were performed with the 
GPU-enabled AMBER16 molecular dynamics package [Case et al., Amber 2016] using 
the CHARMM36m force field for proteins and lipids,[140, 141, 158] and a stream file 
that contains optimized SR parameters, and run at a temperature of 310K (using 
Langevin thermostat) and 1atm pressure (using MC barostat). Periodic boundary 
conditions (PBC) were employed, non-bonded cutoff distance was set to 12 Å, long-
range electrostatic interactions beyond this cutoff were calculated using the particle mesh 
Ewald (PME) method, and all covalent bonds involving hydrogen atoms were 
constrained using the SHAKE algorithm. 
Lipid order parameters and density distributions were calculated using LOOS 
[143]. Tcl tools in VMD were used to calculate area per lipid and dihedral angles 
probability distributions.[144] 
 
Results 
Parameterization: 
Target data: Previously published crystal structures for SR show two different 
crystalline forms that have different dihedral angles between the chlorinated phenyl 
groups and the pyrazole ring, and between the amide group and the piperidine ring (see 
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Fig. 32). In addition, the crystal structure of form I has the dichlorophenyl ring rotated 
180° in 10% of the molecules,[155] with energy barrier of 10 Kcal/mol between the two 
conformations calculated at HF 6-31G* level. To overcome crystal packing and solvation 
effects, and to obtain a reference geometry for CHARMM parameterization, crystal 
structures' geometries were optimized in vacuum using ab initio HF/6-31G* and MP2/6-
31G* levels of theory. 
Crystal structures’ bond lengths were reproduced in the MP2 level of theory 
compared to the HF calculations. QM optimized dihedrals were slightly shifted from 
crystal structures’ dihedrals in both QM methods. MP2 geometry optimization shows that 
form II has a higher (2 Kcal/mol) gas phase potential energy compared to form I, and 
form Ia is lower in energy (0.11 Kcal/mol) than form Ib. In addition, SR global minima 
identified by full conformational search at MP2 level of theory has a similar geometry to 
form Ia, and the rotation of the dichlorophenyl ring in form Ia is similar to the crystal 
structure of AM6538 in complex with the CB1 receptor [15]. Thus, form Ia was used as 
the target geometry for SR bonded parameter optimization, and will be referred to as SR 
global minima.  
Evaluation of initial charges and guess parameters: Paramchem-generated charges 
and guess parameters show high penalties on some charges, bonds, angles and dihedrals. 
SR global minima was minimized in CHARMM to evaluate those parameters before 
starting a full parameterization. CHARMM minimized structure deviates from the global 
minima, specifically at the piperidinyl amide moiety which necessitates partial atomic 
charges and parameter optimization (see Fig. 33).  
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Charge optimization: Hinge on the hierarchical essence of CGenFF parameter 
optimization, charges for SR aromatic rings were obtained directly from the CGenFF, 
and charge optimization was only carried for the piperidinyl amide moiety. The amide 
functional group was capped with a methyl group, and a total of nine separate 
electrostatic interaction complexes were optimized (see Fig. 34). Table 5 shows 
interaction energies and distances for fragment 1-water complexes. Absolute average 
deviation for MM interaction energies and interaction distances compared to HF values 
were 0.11 Kcal/mol and 0.16 Å respectively. Charges of the whole SR were then 
calculated as described in Methods and are listed with atom typing in Table 6. 
 
 
Figure 32. Crystal Structure Geometries for SR. In both conformations, the phenyl 
rings are tilted ~60 degrees from the plane of the pyrazole ring, the amide oxygen is ~20 
degrees from the plane of the pyrazole with trans amide conformation, and the piperidine 
ring lone pair of electrons are either in trans (Form Ia,b), or in cis (Form II) conformation 
with the amide hydrogen. 
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Figure 33. Bond Lengths, Angles, and Dihedrals for SR. Plots of bond lengths, angles, 
and dihedrals measured for SR global minima at MP2 geometry against CHARMM 
minimized structure using initial CGenFF guess parameters (Red circles), and optimized 
parameters (Green boxes). Black line corresponds to MP2 reference values, dotted lines 
correspond to ±0.03 Å, 3°, and 6° margins for bond lengths, angles and dihedrals 
respectively. 
 
 
 
 
Figure 34. Setting SR-Water Interaction Complexes. A) Molecular fragments used to 
set charges for the whole SR. Atom numbers for molecular fragment 1 are indicated. B) 
Interaction complexes between fragment 1 and TIP3 water molecules. Each complex was 
set individually to calculate electrostatic interaction energies and distances for each 
indicated atom.  
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Bonded parameters: SR global minima geometry was minimized again in 
CHARMM using optimized partial charges. Charge optimization significantly enhanced 
the geometry of CHARMM minimized SR. Bonded parameters optimization was based 
on the reproduction of SR global minima geometry (see Fig. 33), as well as the 
reproduction of QM PES for bonds, angles, and dihedrals that deviated by more than 0.03 
Å, 3°, and 6°, respectively from their measures in SR global minima (see Fig. 35, 36, 37). 
Bonded terms parameterization started with parameterizing bond lengths, then angles and 
dihedrals, and required multiple iterations specifically that the parameterization of one 
bonded term may affect the other. Following each iteration, bond lengths, angles, and 
dihedrals were measured for the whole compound and compared with SR global minima 
geometries. Dihedral angles were also measured for SR during the MD simulation and 
dihedral parameters were adjusted to ensure that the dihedral probability distributions are 
in agreement with the QM PES. For the dihedral between the pyrazole and the aromatic 
rings, two energy minima are present with low energy barrier between them, a planar 
geometry with the pyrazole ring is unfavorable due to steric clash with the ortho-
substituents on the pyrazole ring (see Fig. 37A and 37B). The dihedral between the 
piperidine ring and the carboxamide shows a broad local minimum between -80° to -160° 
(see Fig. 37C), this is when the carboxamide oxygen is in cis with the piperidine lone pair 
of electrons and the equatorial aliphatic hydrogens on the piperidine ring (like form II 
crystal structure). Finally, the amid oxygen would have a cis geometry with the methyl 
substituent at the pyrazole ring, this is because the trans geometry would result in steric 
clash between the amide proton and that methyl. 
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Table 5. Interaction Energies and Distances Between Molecular Fragment 1 and 
Water. Differences in CHARMM (MM) and ab-initio (QM) interaction energies ∆E 
(Kcal/mol), and Distances ∆r (Å), of Fragment 1-Water complexes. 
 
 ∆∆ E ∆r 
Interacting complex (MM-QM) (MM-QM) 
O …HOH 0.1 -0.22 
H2’ … OHH -0.06 -0.2 
C4’Ha …OHH  0.25 0.43 
C4’He …OHH -0.07 -0.15 
C5’Ha …OHH 0.13 -0.1 
C5’He …OHH -0.04 -0.09 
C6’Ha …OHH 0 -0.02 
C6’He…OHH 0.11 -0.09 
N3’ … HOH 0.2 -0.11 
Abs Ave. Deviation 0.11 0.16 
Abs. Std. Deviation 0.08 0.12 
 
 
 
 
Figure 35. Potential Energy Scans for Two Bond Lengths in SR. A) Bond length 
between the pyrazole ring and the chlorophenyl ring. B) Bond length between the amide 
nitrogen and the piperidine nitrogen, with similar legend to graph A.  
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Figure 36. Potential Energy Scan for SR Angle. The angle described by the 
carboxamide carbon, the carboxamide nitrogen and piperidine nitrogen 
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Figure 37. Potential Energy Scans and Probability Distributions for SR Dihedrals. 
Graphs show dihedrals between: the amide and the piperidine ring (A), pyrazole and the 
chlorophenyl rings (B), the pyrazole and the dichlorophenyl ring (C), and the pyrazole 
and the amide group (D). Right Axes show relative energies from PES and are displayed 
in black (MP2 PES), Red (initial CGenFF PES), and in green (CHARMM PES using 
optimized parameters). Left axes show the probability distribution from the MD 
simulations of SR in POPC bilayer and are displayed on each graph and colored Grey.  
 
 
MD simulation: Two independent all atom MD simulations were done to study 
the dynamics of SR in a lipid bilayer. In the first simulation, SR was added directly to the 
lipid phase, and dynamics of all six SR molecules in the bilayer was monitored 
throughout the simulation. However, in the second simulation, three SR molecules were 
added to the water phase on each side of the bilayer, and the dynamics of SR partitioning 
A B 
C D 
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into, and inside the bilayer was monitored. In this simulation, only three SR molecules 
from one side of the bilayer partitioned into the lipid bilayer during the first 25ns of the 
simulation, while the remaining SR molecules on the other side of the bilayer clumped 
together inside the water phase and did not diffuse into the lipid phase during the period 
of the simulation.  
Lipid parameters: For both simulations, area per lipid as well as the lipid acyl 
chain order parameters were calculated to verify the accuracy of the lipid simulation. 
Area per lipid was determined by dividing the lateral area, measured in VMD for each 
frame, by the number of phospholipids in each leaflet. Average area per lipid for the last 
200ns for simulation I and II were 67 and 66 A^2 respectively, in agreement with 
experimental values (see Fig. 38). [147]  
 
 
 
Figure 38. Area Per Lipid for the Last 200ns of MD Simulations of SR in POPC 
Bilayer. Simulation I (Red), and simulation II (Blue). 
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Palmitoyl (sn1), and oleoyl (sn2) acyl chains order parameters (SCH) were also 
calculated for both simulations and compared to available experimental data. SCH denotes 
an ensemble average of the relative orientation of the CH bonds with respect to the 
bilayer normal, and defined as (eq. 2): 
 
𝑆𝐶𝐻 =  
1
2
 〈3 cos2 𝜃 − 1〉  eq. (2) 
 
 
Where  is the angle between a C-H bond in acyl chain methylene groups and the 
normal to the bilayer (Z-axis). The angular brackets indicate an ensemble average. 
A 2H solid state NMR study at 35°C reported an increase in the order parameters 
of a dimyristoylphosphatidylcholine (DMPC) bilayer by the addition of 2 mol% AM281 
which is an analogue of SR with a morpholino group substituent at the amide group and a 
p-iodophenyl group instead of the p-chlorophenyl ring in SR.[159] Experimentally 
determined order parameters for the sn1 and the sn2 POPC acyl chains are not available 
at 310K temperature. However, error bars of calculated SCH values for both sn1 and sn2 
chains in both simulations overlap with recently published (NMR-determined at 300K) 
order parameters,[148] and the sn2 oleoyl chain shows the characteristic dip in SCH 
values at carbon 2 and 10 (see Fig. 39).  
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Figure 39. Lipid Order Parameters from MD Simulations of SR in POPC Bilayer. 
Calculated lipid order parameters for the sn1 (Palmitoyl) and the sn2 (Oleoyl) chains of 
POPC. Results from MD simulation run 1 (Blue), run 2 (Red), and NMR experimental 
values (Black).[148] Error bars represent standard error in each MD simulation run. 
NMR reference values were extracted by digitizing plotted graph in the reference 
paper.[148] 
 
 
Density distribution: Density distributions for the bilayer components as well as 
for SR and SR subset groups were calculated and determined for the last 200 ns of each 
simulation. Visual monitoring of the SR behavior in the lipid bilayer shows that SR 
generally sets below the phospholipids glyceryl chain. SR can freely move, rotate and flip 
in all directions in the bilayer, and may also move between leaflets. This is obvious in the 
density distributions where it shows some molecules being distributed in both leaflets 
indicative of movement of SR from one leaflet to the other (see Fig. 40). In addition, the 
random distribution of SR subsets indicates the free behavior of the ligand in the bilayer. 
However, comparing the density distributions of the different subsets of SR shows a 
general trend where the piperidine ring and the amide groups are located closest to the 
phospholipid head groups, the chlorophenyl ring is shifted slightly towards the center of 
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the bilayer, and the dichlorophenyl ring is shifted further. In simulation II, the 
partitioning of SR into the lipid bilayer starts with an interaction of the piperidine and 
amide groups with the phospholipid head groups (see Fig. 41). 
Dihedrals probability distributions: SR dihedrals were measured throughout both 
simulations and compared to QM PES. All dihedral probability distributions acquired 
from simulations were consistent with QM PES (see Fig. 37).  Looking at the probability 
distribution of the dihedral between the piperidine and the amide that a piperidine could 
rotate in the bilayer, and despite that the starting structure had the piperidine ring rotated 
like form I crystal structure, the other form has been populated throughout the simulation 
(see Fig. 37C).  
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Figure 40. Mass-Density Distributions of SR in POPC Bilayer. At the y-axis: mass-
density distributions. Right and Left panels show mass density distributions calculated for 
simulation I and II respectively, Upper most graphs are showing the density distributions 
for the phosphate atoms (Black), glycerol region (Pink) and water (Blue). The rest of the 
panels, each SR molecule is given a distinct color in those distributions, and the 
distribution of SR or SR subsets were calculated for each SR molecule. Measures were 
done for the last 200 ns of simulations. SR subset density distributions for simulation II 
were only done for the SR molecules that partitioned into the lipid. 
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Figure 41. Snapshots from MD Simulation Showing the Diffusion of SR from Bulk 
Water into the POPC Bilayer. SR rotates in all directions and moves freely between 
bilayers. First entry of SR involves an interaction of the piperidine ring with the head 
groups. The phosphorous and nitrogen atoms of the POPC headgroups are shown as gold 
and blue spheres respectively, Water molecules are shown in tube display. POPC carbon 
tail in silver tubes. Color code for SR is: carbons (yellow), nitrogens (Blue), oxygen 
(Red), hydrogens (White) and chlorine (Yellow green). 
 
 
Discussion 
Advances in computer power and algorithms facilitated the use of molecular 
dynamics simulation to predict and understand drug receptor interactions. MD simulation 
studies were done to pursue ligand binding to GPCRs to correlate ligand structure to their 
binding affinity. Using multi-microsecond unbiased MD simulations, Dror and coworkers 
examined the pathway and the interaction dynamics of different ligands with the β1- 
and β2- adrenergic receptors. Their results suggest that ligands that access the receptor 
binding pocket from bulk water would face a large energy barrier during their initial 
association with the receptor due to dehydration process that is necessary to allow the 
hydrophobic interaction with the receptor.[160] Differently, it has been reported that lipid 
derived ligands for GPCRs diffuse from the lipid bilayer to the binding site through 
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transmembrane portal. As an example, 2-AG has been shown to diffuse from the 
phospholipid bilayer to the CB2 receptor’s binding pocket through transmembrane portal 
that was formed between transmembrane helices six and seven upon interacting with the 
ligand.[161] Compared to ligands that access the binding site directly from bulk water, 
the orientation and the depth of lipophilic ligands in a bilayer will affect the binding 
affinity or the binding mode to the receptor.[162] 
Biophysical studies using NMR, X-ray diffraction and differential scanning 
calorimetry were used to investigate the orientation and the dynamics of different 
cannabinoid ligands in the membrane.[159, 162-165] In addition, MD simulation studies 
were used to study the dynamics of anandamide in membrane.[166] Intuitively, 
cannabinoid ligands would orient in the membrane in a way that their polar region orients 
towards the lipid head groups, while their hydrophobic part orients towards the center of 
the bilayer. Results from current work show that SR can move freely in the lipid bilayer. 
Crystal structures of the CB1 receptor with the two different antagonists, Taranabant and 
AM6538, show a common orientation of those ligand in the receptor binding pocket 
having their aromatic rings setting the deepest in the receptor. The presence of aromatic 
residues at the second transmembrane helix near the ligand portal suggests an initial 
aromatic interaction between the ligand and the receptor, and the free movement of SR in 
the bilayer makes it possible for the ligand to form similar aromatic interactions with the 
receptor transmembrane portal.  
 The SAR of biarylpyrazole derivatives has been studied extensively, and the 
affinity of SR to different CB1 receptor mutants has been evaluated. It is worth 
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mentioning that mutating K3.28 in the third transmembrane helix had no effect on the 
binding affinity of Taranabant, while it lowered SR's binding affinity.[118] In a 
thermodynamic cycle study, this amino acid residue was determined to form a key 
hydrogen bond interaction between the carboxamide oxygen of SR and K3.28 that is 
essential for the inverse agonism of biarylpyrazoles.[120] The different effect of mutating 
K3.28 to alanine on the binding affinity of those ligands indicate a different way of the 
binding of those two ligands to the receptor. Availability of force field parameters for SR 
helps elucidating its interaction with the CB1 receptor. 
 
Conclusions 
The CHARMM General Force Field (CGenFF) was created for drug-like 
molecules to use in conjunction with the CHARMM additive biomolecular force field. It 
covers a broad space of chemical groups present in biomolecules and in drug-like 
molecules, including simple functional groups, aromatics, and heterocycles, and it allows 
the extension of the force field to cover additional functional groups with emphasis on 
quantum mechanical (QM) results as target data for parameter optimization.[154] In this 
study, we have reported the force field parameters for SR, which reproduced SR quantum 
mechanical and crystal structure’s geometries during a MD simulation of SR in a lipid 
bilayer. Those parameters can be used to better understand the interaction dynamics of 
SR with the CB1 receptor, and to develop force field parameters for SR analogues, 
helping us better understand the binding affinity data of those analogues not only in the 
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context of drug-receptor interaction, but also in the context of ligand’s behavior in the 
lipid bilayer. 
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Table 6. Listing of Atom Names, Types, and Partial Charges (Q) of SR. 
 
Atom Type q Atom Type Q 
N1 NG2R51 0.251 H6’ HGA2 0.090 
N2 NG2R54 -0.547 C1’’ CG2R65 0.048 
C3 CG2R52 0.246 C2’’ CG2R65 0.047 
C4 CG2R51 -0.072 C3’’ CG2R61 -0.047 
C5 CG2R51 0.113 H3’’ HGR62 0.151 
C6 CG331 -0.261 C4’’ CG2R61 0.047 
H6 HGA8 0.090 C5’’ CG2R61 -0.117 
C1’ CG2O8 0.431 H5’’ HGR62 0.165 
O OG2D1 -0.455 C6’’ CG2R61 -0.117 
N2’ NG2S1 -0.323 H6’’ HGR61 0.115 
H2’ HGP1 0.318 C1’’’ CG2R61 -0.006 
N3’ NG3N1 -0.409 C2’’’ CG2R61 -0.116 
C4’ CG321 0.045 H2’’’ HGR61 0.115 
C5’ CG321 -0.183 C3’’’ CG2R61 -0.114 
C6’ CG321 -0.186 H3’’’ HGR62 0.165 
H4’ HGA2 0.090 C4’’’ CG2R61 0.052 
H5’ HGA2 0.090 Cl CLGR1 -0.146 
 
 
Table 7. Lennard-Johns Parameters for Atom Types Used in SR Topology File. New 
atom types were added to the stream file to ensure that fixed angle or dihedral terms do 
not affect the force field parameters for other molecules already parameterized in 
CGenFF. 
 
Atom type ε rmin Atom type ε rmin 
CG2O8 -0.110 2.0000 HGA8 -0.024 1.3400 
CG2R51 -0.050 2.1000 HGP1 -0.046 0.2245 
CG2R52 -0.020 2.2000 HGR61 -0.030 1.3582 
CG2R61 -0.070 1.9924 HGR62 -0.046 1.1000 
CG2R65 -0.070 1.9924 NG2R51 -0.200 1.8500 
CG321 -0.050 2.0100 NG2R54 -0.200 1.8500 
CG331 -0.780 2.0500 NG2S1 -0.200 1.8500 
CLGR1 -0.320 1.9300 NG3N1 -0.060 2.0500 
HGA2 -0.035 1.3400 OG2D1 -0.120 1.7000 
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Table 8. SR Bond Parameters. 
 
Type Type Kb b0 Type Type Kb b0 
CG2O8 CG2R52 300.0 1.4750 CG2R65 CLGR1 350.0 1.7260 
CG2R51 CG2R61 400.0 1.4400 CG2R52 NG2R54 400.0 1.3560 
CG2R65 NG2R51 400.0 1.4150 NG2R54 NG2R51 360.0 1.3500 
CG321 NG3N1 263.0 1.4730 CG2O8 OG2D1 620.0 1.2400 
NG2S1 NG3N1 360.0 1.4011 CG2O8 NG2S1 370.0 1.3450 
CG2R65 CG2R65 394.0 1.3750 CG331 HGA8 170.0 1.0700 
CG2R65 CG2R61 394.0 1.3750     
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Table 9. SR Angle Parameters. 
 
Type Type Type 𝑲𝜽 𝜽𝟎 𝑲𝒃𝟏−𝟑  𝒃𝟎
𝟏−𝟑 
CG2R52 CG2O8 NG2S1 80.00 113.57   
CG2R52 CG2O8 OG2D1 30.00 121.65   
CG2R51 CG2R51 CG2R61 45.80 131.33   
CG2R52 CG2R51 CG331 45.80 128.06   
CG2R61 CG2R51 NG2R51 45.80 122.45   
CG2R51 CG2R61 CG2R61 36.00 119.91   
CG321 CG321 NG3N1 0.04 108.70   
NG3N1 CG321 HGA2 32.40 109.50 50.00 2.13 
CG2O8 NG2S1 NG3N1 50.00 120.00   
NG3N1 NG2S1 HGP1 35.00 115.93   
CG321 NG3N1 CG321 40.50 112.02 5.00 2.443 
CG321 NG3N1 NG2S1 0.03 111.65 99.00 2.38 
CG2R65 CG2R65 NG2R51 60.00 121.61   
CG2R61 CG2R65 NG2R51 60.00 118.45   
CG2R51 NG2R51 CG2R65 70.00 128.04   
CG2R65 NG2R51 NG2R54 70.00 118.83   
CG2R61 CG2R65 CLGR1 60.00 120.00   
CG2R65 CG2R65 CLGR1 60.00 120.00   
CG2R65 CG2R65 CG2R61 40.00 119.85 35.00 2.42 
CG2R65 CG2R61 CG2R61 40.00 119.39 35.00 2.41 
CG2R65 CG2R61 HGR61 30.00 119.98 22.00 2.15 
CG2R65 CG2R61 HGR62 30.00 120.00 22.00 2.15 
CG2R52 NG2R54 NG2R51 160.00 103.94   
CG2R51 NG2R51 NG2R54 160.00 113.13   
CG2R51 CG2R52 CG2O8 0.02 124.60 125.00 2.51 
NG2R54 CG2R52 CG2O8 50.00 120.59   
CG2R51 CG2R52 NG2R54 110.00 112.33   
NG2S1 CG2O8 OG2D1 80.00 124.78   
CG2O8 NG2S1 HGP1 34.00 123.00 143.00 2.12 
CG2R51 CG331 HGA8 55.00 110.33   
HGA8 CG331 HGA8 35.50 109.55 5.40 1.80 
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Table 10. SR Dihedral Parameters.  
 
Type Type Type Type K n  
NG2S1 CG2O8 CG2R52 CG2R51 4.6 2 180 
NG2S1 CG2O8 CG2R52 NG2R54 0.0 2 180 
OG2D1 CG2O8 CG2R52 CG2R51 1.0 3 180 
OG2D1 CG2O8 CG2R52 NG2R54 1.0 3 180 
CG2R52 CG2O8 NG2S1 NG3N1 1.6 2 180 
CG2R52 CG2O8 NG2S1 HGP1 4.0 2 180 
OG2D1 CG2O8 NG2S1 NG3N1 1.0 2 180 
CG2R52 CG2R51 CG2R51 CG2R61 0.0 2 180 
CG2R61 CG2R51 CG2R51 CG331 0.0 2 180 
CG2R51 CG2R51 CG2R52 CG2O8 2.0 2 180 
CG331 CG2R51 CG2R52 CG2O8 6.9 2 180 
CG331 CG2R51 CG2R52 NG2R54 15.0 2 180 
CG2R51 CG2R51 CG2R61 CG2R61 3.0 2 180 
NG2R51 CG2R51 CG2R61 CG2R61 3.0 2 180 
CG2R61 CG2R51 NG2R51 NG2R54 1.0 2 180 
CG2O8 CG2R52 NG2R54 NG2R51 1.0 2 180 
CG2R51 CG2R61 CG2R61 CG2R61 10.0 2 180 
CG2R51 CG2R61 CG2R61 HGR61 12.0 2 180 
CG2R61 CG2R61 CG2R61 NG2R51 3.1 2 180 
CG321 CG321 CG321 NG3N1 2.4 2 0 
NG3N1 CG321 CG321 HGA2 5.0 3 0 
CG321 CG321 NG3N1 CG321 0.4 3 0 
CG321 CG321 NG3N1 NG2S1 0.2 3 0 
HGA2 CG321 NG3N1 CG321 3.0 3 180 
HGA2 CG321 NG3N1 NG2S1 2.0 3 180 
CG2O8 NG2S1 NG3N1 CG321 0.0 2 0 
HGP1 NG2S1 NG3N1 CG321 0.0 1 0 
CG2R65 CG2R65 CG2R61 CG2R61 2.0 2 180 
CG2R61 CG2R65 CG2R65 CG2R61 0.0 2 180 
CG2R61 CG2R61 CG2R61 CG2R65 3.1 2 180 
CG2R61 CG2R61 CG2R65 CLGR1 3.1 2 180 
CG2R61 CG2R65 CG2R65 CLGR1 3.1 2 180 
CG2R65 CG2R61 CG2R61 CLGR1 3.0 2 180 
CG2R51 CG2R51 NG2R51 CG2R65 3.0 2 180 
CG2R61 CG2R51 NG2R51 CG2R65 3.0 2 180 
CG2R61 CG2R65 CG2R65 NG2R51 3.0 2 180 
CG2R61 CG2R61 CG2R65 NG2R51 3.0 2 180 
NG2R51 CG2R65 CG2R65 CLGR1 5.0 2 180 
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Table 10 (Continued), SR Dihedral Parameters.  
 
Type Type Type Type K n  
NG2R51 CG2R65 CG2R61 HGR61 5.0 2 180 
CG2R65 CG2R65 CG2R61 HGR61 2.4 2 180 
CG2R65 CG2R61 CG2R61 HGR61 3.0 2 180 
CG2R61 CG2R65 NG2R51 CG2R51 4.2 2 180 
CG2R65 CG2R65 NG2R51 CG2R51 4.2 2 180 
CG2R65 CG2R65 NG2R51 NG2R54 1.2 2 180 
CG2R61 CG2R65 NG2R51 NG2R54 1.2 2 180 
CG2R52 NG2R54 NG2R51 CG2R65 8.5 2 180 
CG2R65 CG2R61 CG2R61 HGR62 4.2 2 180 
CG2R65 CG2R65 CG2R61 HGR62 4.2 2 180 
HGR62 CG2R61 CG2R65 CLGR1 3.0 2 180 
CG2R51 CG2R51 CG2R52 NG2R54 8.5 2 180 
CG2R51 CG2R51 NG2R51 NG2R54 10.0 2 180 
CG2R52 NG2R54 NG2R51 CG2R51 12.0 2 180 
CG2R51 CG2R52 NG2R54 NG2R51 12.0 2 180 
OG2D1 CG2O8 NG2S1 HGP1 2.5 2 180 
CG2R51 CG2R51 CG331 HGA8 0.1 3 180 
CG2R52 CG2R51 CG331 HGA8 0.0 3 0 
IMPROPERS 
CG2O8 CG2R52 NG2S1 OG2D1 120.0 0 0 
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CHAPTER V 
 
CONCLUSIONS 
 
 
Three different studies were presented in this work. In the first study, we could 
demonstrate the function of conserved amino acid residues in dictating the signaling 
pathways via the CB1 receptor. In specific, proposed mutants were focused on stabilizing 
a rotameric state of Y7.53 that biases the signaling of the CB1 receptor towards the β-
arrestin pathway. Resulting mutants were well expressed, and were successful in 
generating a G-protein independent, yet β-arrestin dependent pERK signal. Orthosteric 
ligands that bias the signaling of the CB1 receptor towards the β-arrestin pathway are not 
known yet, and resulting mutants can be used in structure-based drug design of such 
selective ligands. In addition, biased mutants assist drug discovery for novel therapeutics 
that target the CB1 receptor, and provide the ability to study the correlation of CB1 
receptor to different diseases including neurodegenerative diseases. Most importantly, the 
elucidation of the role of conserved amino acid residues in dictating conformational 
changes at the IC domain of the CB1 receptor is an integral part in understanding the 
selective coupling of this receptor to the different IC effector proteins, and can be applied 
to other members of class A GPCRs.  
Availability of structural information of proteins and chemical compounds is 
integral in drug design. Computational methods provide a broader view of drug receptor 
interactions and better understanding of protein structure and its dynamics in its 
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biological environment away from the static crystalline state. In the second study, we 
addressed the N-terminus of the CB1 receptor in its inactive state crystal structure being 
invading the receptor’s binding site, which will affect future modelling studies and 
structure-based drug design for new CB1 receptor antagonists based on the crystal 
structure. We could determine via MD simulations the binding site of 14h, as well as 
detailed description of the TMH1/7 portal at the CB1 receptor which allows the entry of 
CB1 receptor antagonists. In addition, the presented model of the N-terminus was stable, 
and improved the stability of the receptor in its inactive state determined via MD 
simulations. 
Finally, results from the MD simulations of 14h and SR in POPC bilayer 
emphasize on the role of the ligand’s dynamics in the lipid bilayer in dictating the initial 
interaction with the receptor at the transmembrane portal, thus controlling ligand’s 
affinity. Presented studies provide new perspective in designing new antagonists that 
target the CB1 receptor.  
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